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Executive Summary 
 
Background 
Older individuals generally suffer from multiple co-morbidities and this makes this 
patient group particularly vulnerable to inappropriate prescribing (IP).  IP has been 
reported to be a substantial cause of morbidity and mortality and has been identified 
as a major contributing factor to increased healthcare utilisation.  One method of 
evaluating or identifying inappropriate or sub-optimal prescribing practice is to use 
validated evidence-based explicit criteria to define instances of potential IP.  Two 
sets of criteria have gained international recognition, i.e. Beers’ criteria and 
“Screening Tool of Older Peoples Prescriptions (STOPP)”.  
 
Aim 
The aim of this study was to determine the prevalence of potential IP in older nursing 
home residents on the island of Ireland. 
 
Methods 
A total of 315 residents ≥65 years were randomly selected from fourteen nursing 
homes from County Cork, Ireland and were age and gender matched with 315 
residents from a Northern Irish nursing home dataset.  Exclusion criteria included 
terminally ill or respite patients.  Both the Beers’ and STOPP criteria were applied to 
the patient profiles of the 630 residents in both Northern Ireland (NI) and the 
Republic of Ireland (RoI). 
 
Results 
Of the residents reviewed (n=630), 472 (74.9%) were female; the median age was 
84 (IQR: 78-89) of the entire dataset. The total number of medicines prescribed for 
the RoI dataset was 3,730 (median 11, IQR 9-13) and for the NI population was 
3,394 (median 10, IQR 7-13). In the RoI dataset, 73.0% of residents had at least one 
potentially inappropriate medication (PIM) identified by STOPP criteria and 54.3% 
had at least one PIM identified by the Beers’ criteria.  In the NI dataset 67.0% of 
residents had at least one PIM identified by STOPP criteria and 56.8% of residents 
had at least one PIM identified by the Beers’ criteria.  
 
Conclusion 
Potential IP is a major area of concern and has been implicated throughout the 
literature as a substantial burden to health services internationally.  In this study 
STOPP criteria demonstrated superior capability over the Beers’ criteria in the 
identification of instances of potential inappropriate prescribing (PIP) in these nursing 
home / long term care facility residents.  
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1.0 Introduction 
Most of the research (Tables 1-3) to date has outlined the prevalence of potentially 
inappropriate prescribing (PIP) in community dwelling older patients.  Elderly 
individuals residing permanently in long term care facilities have generally been 
excluded from these studies.  In 2006, it was reported that 5.5% of the Irish 
population aged over 65 years were permanently residing in long term care facilities 
and 2007 census data reported that 22.7% of people aged over 85 years were 
resident in such facilities (Barry  et al. 2006; Central Statistics Office 2007).  Given 
the anticipated growth in the Irish older population expected over the next few 
decades, there will probably be corresponding increases in the number of older 
individuals requiring long term care.  Several studies in the recent literature 
evaluating PIP in residents residing in these facilities have demonstrated large rates 
of PIP occurrence (Tables 1-3).  The aim of this study is to determine and compare 
the rates of PIP in older Irish residents residing in these settings both in Northern 
Ireland and the Republic of Ireland.  
1.1 The Ageing Population 
People over 65 years commonly suffer from multiple co-morbidities and routinely 
prescribed multiple medications to treat these different conditions when compared to 
their younger counterparts (Barry et al. 2006).  Epidemiological data from Europe 
indicates that older people 65 years and older take 2.3 times more medication than 
younger counterparts (Barry et al. 2006).  In a 2002 study it was estimated that 
approximately 11.5% of the Irish population is 65 years and over and it is reported 
that this portion of the population regularly receives almost 47% of all the prescribed 
medications in Ireland (Barry et al. 2002).  This proportion of the population that live 
to over 65 years has increased over the last 50 years, with the number of older 
people almost tripling, and it is expected that it may almost triple again over the next 
50 years (World population ageing 1950-2000).  This predicted increase in the older 
population could potentially result in a major socio-economic problem and it warrants 
consideration as it means that caring for older individuals could become more 
significant and demanding (Barry et al. 2006).  
 
A number of frailer older individuals who suffer from multiple chronic co-morbidities 
are unable to effectively care for themselves and often require admission to a long 
term care facility so as to receive adequate continual care. It is estimated that 
approximately 5.5% of Irish people aged over 65 years are permanently resident in 
long term care facilities, with an even higher percentage of older elders requiring 
long term care.  This is illustrated by the 2007 census report which found that 22.7% 
of individuals aged over 85 years were resident in long term care facilities (Central 
Statistics Office 2007).  
 
The fact that older individuals generally are more likely to suffer from multiple chronic 
morbidities, which usually require the use of long term complex medication regimens 
to treat each individual condition, places this patient group at increased risk of 
experiencing an adverse drug event (ADE) or a drug-drug interaction (Liu et al. 
2003).  This fact, coupled with an expected increase in an individual’s longevity 
which is predicted over the next 50 or so years, could potentially mean that the 
medication usage by the older patient group will probably increase and place an 
already vulnerable patient group at an increased risk of inappropriate prescribing 
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(IP).  Polypharmacy has been identified throughout the literature as a significant 
predictor of IP prevalence.  A number of studies have reported a high prevalence of 
IP in the older population, which in turn has been identified as a major contributory 
factor in patients experiencing an adverse drug event (ADE).  An increased 
incidence of ADE has been reported to correlate with increased mortality, morbidity 
and healthcare utilisation (Hamilton et al. 2009).  Similarly, it has been reported that 
older patients who reside in long term care facilities are particularly vulnerable to IP.  
These individuals generally suffer from an increased incidence of functional 
disabilities as well as suffering from more acute and chronic co-morbidities as 
opposed to community dwelling older counterparts.  This high incidence of multiple 
morbidities usually means that this patient group requires long term complex 
medication regimens (Rancourt et al. 2006).  
1.2 Pharmacotherapy 
Optimal prescribing is a crucial aspect of gerontology.  The main aim of prescribing 
is to cure disease, eliminate or reduce symptoms relating to an underlying disease 
state and improve functional capacity of the patients (Hanlon et al. 2001). 
1.2.1 Appropriate Prescribing 
Appropriate prescribing is a general concept that encompasses a variety of different 
prescribing values and practices.  Appropriate prescribing is essentially a phrase 
used to quantify / measure the quality of prescribing (Spinewine et al. 2007).  
Several important factors need to be taken into consideration when defining 
appropriate prescribing practices for a patient (Spinewine et al. 2007): 
• What the patient wants, 
• What the patient needs and; 
• Scientific rationalism (including the clinical pharmacology of certain drugs). 
However prescribing in older patients is complicated by a number of factors and 
these usually need to be taken into consideration when prescribing for such a patient 
(O’Mahony et al. 2008): 
• Life expectancy of the patient, 
• The right therapeutic approach in patients with poor prognosis and; 
• Selection of the pharmacotherapy with the most favourable risk/benefit ratio. 
1.2.2 Inappropriate Prescribing 
Inappropriate Prescribing (IP) is a universal term used to describe a number of sub-
optimal prescribing practices but essentially is the use of a particular medicine for 
which the risks associated with its use outweigh the potential benefits especially 
when there are as effective, safer alternatives available for treatment of the same 
condition (Beers et al. 1997; Spinewine et al. 2007).  The definition of 
inappropriateness is usually considered to be relative rather than absolute; this 
relates to the fact that under certain circumstances medications which are deemed 
generally inappropriate might in fact have an appropriate indication e.g. furosemide 
as monotherapy to treat hypertension when other anti-hypertensives have failed 
(Fialova et al. 2005). 
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IP has become an area of major concern in the older population (Barry et al. 2006).  
It has been widely documented that certain drugs should be used cautiously in this 
patient group, and it is generally best to completely avoid them in older patients if a 
safer alternative is available.  
 
The concept of IP encompasses several aspects of prescribing as follows: 
• Over prescribing of medication i.e. polypharmacy, relates to the practice of 
prescribing multiple medications or more medications that are clinically required.  
• Over prescribing also encompasses the practice of prescribing medications at 
higher doses or frequencies for periods longer than are clinically indicated. 
• IP entails the prescribing of a medication where the risks of an adverse event 
associated with its use outweigh the clinical benefits, especially when there is 
evidence to support the use of a safer more effective alternative therapy for the 
same condition i.e. an unfavourable risk benefit ratio.  
• IP also encompasses the prescribing of medications with high inherent risk of 
adverse drug-drug or adverse drug-disease interactions. 
• The practice of prescribing certain medications that are not clinically beneficial or 
indicated for a specific patient.  
• The prescribing of medications which may fulfil an intended therapeutic purpose 
but for which a more effective agent is available. 
• Prescribing of a drug or drug class that are likely to exacerbate a clinical problem 
in older patients, e.g. the use of benzodiazepines in older patients with a past 
history of falls. 
• Underuse of medications or under prescribing, is the failure to prescribe a 
clinically beneficial medication to a patient for whom there is no valid reason not 
to prescribe the said medication and for which there is no contra indication to this 
beneficial pharmacotherapy e.g. when a patient suffers from a particular 
condition and there is no drug prescribed to treat this indication, or the dose of 
the drug is not sufficient to effectively treat this condition.  
(Barry et al. 2007; Fialova et al. 2005; Gallagher et al. 2007; Rojas-Fernandez et al. 
2003; Spinewine et al. 2007; Steinman et al. 2006) 
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1.2.3 Inappropriate Medications 
A potential inappropriate medication (PIM) is a medication which possesses an 
unfavourable risk-benefit ratio i.e. a medication for which the risks associated with 
using a particular medication outweighs the benefits of using said medication, 
especially when there are effective, safer alternatives available.  The term potential 
is important as in some cases the prescriber may have considered alternative 
therapies but for a reason unknown to the researcher may have chosen to proceed 
with a given course of treatment. 
 
A number of medications exhibit an increased potential to cause problems in older 
individuals and these medications have been categorised as potentially inappropriate 
for use in older patients. Medications which are identified as high risk or potentially 
inappropriate in older patients do not cause problems in all older patients but do 
have an increased potential to cause harm (Chukta et al. 2004). 
 
In general a PIM in older patients is defined as a medication which (O’Mahony et al. 
2008): 
• Has no clear evidence based indication, 
• Has a substantial higher risk of causing an  ADE and; 
• Is not considered cost effective. 
1.2.4 Screening Tools to Assess Inappropriate Medications 
Screening tools to assess the appropriateness of prescribing identified in the 
literature contain either explicit or implicit criteria or a combination of both.  Explicit 
criteria are specific statements of inappropriateness, originating from evidence based 
guidelines, reviews, expert opinions and consensus techniques.  Explicit criteria are 
generally drug or disease orientated and require a limited degree of clinical 
judgment. In contrast, implicit criteria are clinical judgment based and are not specific 
to any particular drug or disease.  Clinicians using implicit criteria use patient-specific 
data and published work to make judgments about the appropriateness of 
medication usage in patients (Spinewine et al. 2007). 
1.2.4.1 Explicit criteria 
Several studies have been conducted to determine and formulate lists of explicit 
criteria.  These are generally given names of the study investigators or group in 
which they were conducted.  Some of these studies are described below: 
 
McLeod 
McLeod et al. developed a Canadian consensus-based, explicit list of criteria to 
identify PIP in older patients in 1997.  The criteria were validated by a panel of 32 
experts in geriatric pharmacotherapy from diverse locations in Canada and consisted 
of clinical pharmacologists, geriatricians, GPs and pharmacists.  The final list of 
criteria contains 38 scenarios of PIP (18 medications contraindicated in older adults, 
16 drug-disease interactions and 4 drug-drug interactions that should be avoided in 
the older person) (McLeod et al. 1997).  The criteria are divided into four main 
headings: medicines for the Cardiovascular System (CVS) (n=8), psychotropics 
(n=12), non-steroidal anti-inflammatory drugs (NSAIDs) (n=11) and miscellaneous 
(n=7).  Each criterion was qualified with a statement of a risk to patients and an 
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alternative therapy was suggested.  For example, under the CVS, the prescribing 
practice of calcium-channel blockers (CCBs) to treat hypertension for patients with a 
history of heart failure was considered inappropriate as it may worsen heart failure. A 
diuretic and/or an Angiotensin-converting Enzyme (ACE) Inhibitor were 
recommended to replace the CCBs for this criterion.  Scenarios where certain 
medicines were not appropriate, given a patient’s condition, were listed along with 
some drug-drug interactions to be avoided.  
 
This screening tool did not address under-prescribing of indicated medicines (PPOs) 
and did not state medication dosages that should be avoided in older patients.  
Three criteria have been superseded with newer evidence and eight of the 
medicines listed relating to six of the criteria in the screening tool are not available in 
either Northern Ireland (NI) or the Republic of Ireland (RoI). 
 
Improving Prescribing in the Elderly Tool (IPET) 
Naugler et al. formulated the Improving Prescribing in the Elderly Tool (IPET) 
(Naugler et al. 2000). It is a Canadian guideline which was derived from the criteria 
developed by McLeod et al., based on the most prevalent instances of PIP found in a 
geriatric unit using the McLeod criteria.  IPET lists 14 different drug/disease 
interactions which should be avoided in the older person but does not address the 
occurrence of potential prescribing omissions (PPOs).  This tool has not been widely 
or extensively used in determining PIP, possibly owing to its brevity and that one of 
the listed instances of PIP has been superseded with newer evidence i.e. it states 
that β blockers should not be used in patients with CCF (Foody et al. 2002). 
 
Beers’ Criteria 
Beers’ criteria, a United State (US) based guideline, was originally formulated in 
1991 (Beers et al. 1991).  This screening tool contains a list of 30 medicines that 
should not be used in older patients.  It was compiled for nursing home residents 
who are considered frailer, older and sicker than the general elderly population.  The 
authors therefore cautioned that modifications may be necessary if the criteria were 
to be applied to older patients in a non-nursing home setting.  The 1991 criteria were 
updated and expanded in 1997 to make the criteria more applicable to the general 
older population (Beers 1997).  
 
The guidelines consist of two different lists or situations in which medicines should 
be avoided; one considering diagnosis (CD) and one independent of diagnosis (ID). 
Doses or frequencies of administrations that should not be exceeded were also 
listed.  The 1997 criteria were revised and updated in 2003 (Fick et al. 2003). A 12-
member expert panel consisting of psychopharmacologists, pharmaco-
epidemiologists, clinical geriatric pharmacologists and clinical geriatricians from 
diverse geographical locations in the US completed the study which used a modified 
Delphi technique to reach consensus for each criterion.  Eleven criteria that were 
listed in the 1997 tool were excluded from the 2003 list, one from the ID lists 
(phenylbutazone) and ten from the CD lists.  Twenty five medicines were added to 
the ID list and 19 were added to the CD list.  Four criteria were modified.  The new 
criteria list 48 medicines ID and 20 medicines CD that should be avoided.  It also 
rates the severity of the PIM into instances of “high severity” or “low severity” and 
provides a qualifying statement as to why the scenario is considered potentially 
inappropriate.  For example, the prescribing of amiodarone is a PIP of “high severity” 
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ID as amiodarone is associated with QT interval problems and risk of provoking 
torsades de pointes and there is a lack of efficacy in older adults (Fick et al. 2003). 
 
Beers’ criteria were adapted as a standard by Centers for Medicare and Medicaid 
Services in 1999 for nursing home care patients and were included in the 2005 
National Health Care Quality Report as a measure of use of inappropriate 
medications in the elderly (Hustey 2008). Beers’ criteria do not address errors of 
prescribing omission and list several medicines as inappropriate that are not 
available or prescribed in Northern Ireland and the Republic of Ireland. 
 
Screening Tool of Older People’s potentially inappropriate Prescriptions 
(STOPP) and Screening Tool to Alert doctors to Right i.e. appropriate, 
indicated but often omitted Treatments (START) 
Screening Tool of Older People’s Prescriptions (STOPP) and Screening Tool to Alert 
doctors to Right i.e. appropriate, indicated but often omitted Treatments (START) 
were formulated collaboratively by the Department of Geriatric Medicine, Cork 
University Hospital (CUH) and the School of Pharmacy, University College Cork 
(UCC) (Gallagher et al. 2008).  The new screening tool addresses common 
instances of PIP (STOPP) and potential prescribing omissions (PPOs) (START).  
 
The STOPP tool lists 65 instances of PIP and is divided into ten sections according 
to the physiological systems to which the instance of PIP relate.  The START tool 
lists 22 common instances of PPOs divided into six physiological systems to which 
the PPOs pertain.  The initial list of criteria was formulated based on a combination 
of evidence and common instances of PIP and PPOs observed throughout clinical 
working practice.  
 
The STOPP and START tools were validated by the Delphi validation method. 
Eighteen experts in geriatric pharmacotherapy from diverse geographical locations 
throughout Ireland and the UK rated their level of agreement with each criterion on a 
five-point Likert scale.  The experts included consultants in geriatric medicine, 
psychiatry of old age, clinical pharmacologists, senior academic primary care 
physicians and senior hospital pharmacists with an interest in geriatric medicine.  
 
Agreement was achieved by the first Delphi validation round for all of the 22 criteria 
in the START tool and therefore all of these were included in the final published 
version of the START tool.  Two postal rounds of the STOPP tool were required as 
the panel did not reach full consensus on the first round, the initial STOPP tool 
contained 68 criteria and the final STOPP tool contained 65 criteria. 
 
A number of studies have reported on the prevalence of IP in the older population 
from different health care settings.  Table 1-3 below summarise the published papers 
to date which have evaluated the incidence of IP in older patients using the Beers’ 
and STOPP criteria.  
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2.0 Aims 
The aims of this study were to:  
1. Assess the prevalence of potentially inappropriately prescribed (PIP) medicines 
in residents 65 years and older in long term care facilities in both Northern 
Ireland (NI) and the Republic of Ireland (RoI) using both the STOPP screening 
tool and the Beers criteria; to evaluate prescribing practices between NI and RoI 
and to evaluate the prevalence of inappropriate prescribing in both jurisdictions.  
2. Evaluate the effectiveness of both screening tools for identification of 
inappropriate prescribing (IP) in both population groups and evaluate the 
applicability of STOPP as a screening tool in both jurisdictions. 
3. Analyse prescribing practices between the Northern Ireland and the Republic of 
Ireland and to make relevant recommendations to the chief medical officer of the 
care facilities in the RoI dataset.  
4. Economically quantify the ingredient costs of the potential inappropriate 
medicines (PIMs) in both jurisdictions. 
2.1 Objectives 
The objectives of this study were to: 
1. Quantify rates of PIMs amongst a random selection of older long-term residential 
patients in both NI and greater Cork regions using the STOPP criteria and Beers' 
criteria. 
2. Compare the efficacy of these two tools for PIM identification in both populations 
and evaluate the applicability of the STOPP criteria in both jurisdictions. 
3. Economically quantify the ingredient costs in both jurisdictions of the PIMs 
identified. 
4. Evaluate the opinions of long term care residence with regards to their 
pharmacotherapy treatments. 
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3.0 Method 
Ethical approval was granted for this study by the Clinical Research Ethics 
Committee of the Cork Teaching Hospital and University College Cork (Appendix 1 & 
2). All publicly funded nursing homes/ community hospitals within one hour travelling 
time from Cork City (n=15) were written to and asked to be involved in the study.  
Fourteen facilities agreed to take part in the study, one facility declined.  
 
Data pertaining to residents in Northern Ireland was collected as part of the 
Fleetwood Northern Ireland study; further information is given below. 
3.1 Data collection 
3.1.1 Republic of Ireland 
In the Republic of Ireland (RoI) arm of the study all the medical information data for 
each individual resident was collected using a computerised collection proforma 
created in Microsoft Access
TM
 2007 which was developed in partnership with 
representatives from the Pharmaceutical Care Research Group from the School of 
Pharmacy, University College Cork and the Clinical Pharmacy Research Group, 
School of Pharmacy, Queen’s University Belfast.  This proforma was piloted on 20 
residents and was subsequently modified in order to improve usability.   
 
Data collection was undertaken by a research assistant from the Pharmaceutical 
Care Research Group from the School of Pharmacy, University College Cork, who 
was sufficiently trained in data collection and application of the STOPP criteria and 
the Beers’ criteria.  The data collection was carried out over a 10 month period on a 
part-time basis between December 2009 and September 2010.  Type of data 
collected included the current medication prescribed, medical diagnosis (current and 
past), the most up to date biochemical data as well as information relating to present 
and past history of falls.  The medical information of the residents was recorded in 
the Access® database and was later exported to Predictive Analytics SoftWare 
Statistics (PASW) (SPSS Inc. Chicago, Ill.) version 18.0 for statistical analysis. 
 
The medical notes of all residents in the fourteen facilities were prospectively 
reviewed and were allocated a unique identification number (1-732) at the point of 
recruitment for data analysis purposes. The data was then subsequently anonymised 
to all except for the research assistant for confidentiality purposes.  All relevant 
diagnosis and medical histories were recorded in the electronic proforma for each 
individual resident.  During the data collection and analysis aspect of the study 
random checks of the work was conducted by the principal investigator, Dr Stephen 
Byrne, to ensure consistency of results.  Other co-investigators on this project were 
contactable at all times to liaise with the research assistant if and when queries 
arose.  
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3.1.2 Northern Ireland 
The data relating to the residents for the Northern Ireland (NI) arm of the study had 
been previously compiled in a dataset using Microsoft Access® 2007 as part of the 
2006-2007 Northern Irish Fleetwood study (Patterson et al. 2010) and subsequently 
exported into Predictive Analytics SoftWare Statistics (PASW) (SPSS Inc. Chicago, 
Ill.) version 18.0 for statistical analysis.   
 
In the NI arm of the study all the patient identifiable information had been previously 
anonymised and each resident had already been allocated an individual identification 
number.  Subsequently all the disease states, medical conditions and medications 
for both datasets were then recoded using internationally recognised coding systems 
in order to aid data analysis.  
 
Data was collected for 732 residents in the RoI arm of the study and this data was 
subsequently age and gender matched with the 334 residents from the NI dataset.  A 
total of 315 residents from each dataset were successfully matched; it was not 
possible to match 19 of the NI 334 residents.  Data were matched by stratification of 
residents’ age and gender using PASW.  The results to follow will report on the 
findings of the matched datasets. 
3.1.3 Diagnoses codes 
The disease states in the study were coded using the World Health Organisation’s 
(WHO) disease states classification system, the International Classification of 
Diseases 10 (ICD-10), to the second level in order to standardise the data between 
the two datasets.  These codes were used for data analysis purposes.  
3.1.4 Medication codes 
The medications were coded using the WHO hierarchal Anatomical Therapeutic 
Chemical (ATC) Classification System (11th edition, 2008) (Appendix 3).  Each 
medicine was assigned a seven digit code in accordance with the ATC classification 
system.  This classification system divides medicines into different groups according 
to the organ or system on which they act and/or their therapeutic and chemical 
characteristics by assigning them an individualised seven alpha-numerical code.  
 
E.g.   Atorvastatin = C10AA05  
where:  C = Cardiovascular System 
  C10 = Lipid Modifying Agents 
  C10A = Lipid Modifying Agents, Plain 
  C10AA = HMG CoA reductase inhibitors 
C10AA05 = Atorvastatin 
 
These codes were then used in data analysis; coding in this fashion facilitated 
analysis of medicines by class or by individual agents. 
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3.1.4 Determining the level of co-morbidity  
The Charlson’s Comorbidity Index (CCI) (Appendix 4) was applied to each patient’s 
profile of the residents from both datasets.  The CCI is a weighted index that takes 
into account the number and seriousness of co-morbid disease in determining a 
resident’s health status (Charlson et al. 1987).  It consists of a list of 17 clinical 
conditions that are ranked on a score of 1-6 in terms of the seriousness of co-morbid 
disease (e.g. residents with a history of a myocardial infarction have a score of 1, 
while residents with concurrent malignant tumours have a score of 6 (Appendix 4).  
3.2 Determining the prevalence of PIP 
The screening tools used to identify PIP were: Beers criteria (Appendix 5) and 
STOPP (Appendix 6). Each screening tool was applied to all the patient profiles of all 
residents in each dataset.  For criteria that listed a class of medicines as potentially 
inappropriate, the most recent British National Formulary (BNF 59th Edition) available 
to the research assistant during the study period was consulted in order to classify 
the medicines (March 2010).  
3.3 Calculation of the Net Ingredient Cost (NIC) 
The net ingredient cost (NIC) was calculated for each medication identified as 
potentially inappropriate by each screening tool.  The prices for the medications in 
the RoI dataset were obtained from the Irish Pharmacy Union’s (IPU) January 2010 
price list.  If a medicine was prescribed by brand the cost price of the cheapest 
version of this brand (i.e. parallel imports) was used and if a medicine was 
prescribed generically the price of the cheapest available generic was used. For the 
NI dataset the prices for the medications were obtained from the January 2010 
Northern Irish Drug Tariff and for any medications not listed in the Drug Tariff the 
price was obtained from the Health and Social Care Business Services Organisation 
January 2010 Pricing Book. The NIC price was calculated for a period of 28 days 
and for medications prescribed as required (pro re nata) “prn”, the price of a 7 day 
supply was used. The NIC was then used to estimate the cost implications of PIP as 
identified by each individual screening tool. The total price was calculated for the 
instances of PIPs including and excluding “prn” medications on a monthly and 
annual basis both in euro and in sterling for both jurisdiction to allow for ease of 
comparison. The overall price of the monthly and annual instances of PIP identified 
by each tool across the entire dataset was also calculated in both euro and sterling.  
The conversion rate used for the purpose of this study was £1 = €1.135.  The pricing 
represents only the NIC and did not reflect the entire costs involved as, for example, 
dispensing costs and VAT (where applicable) were not included. 
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3.4 Statistical Analysis  
To determine the type of data i.e. parametric or non-parametric, the normality of the 
data was established by a review of the age distribution histogram and the boxplot 
and by performing Kolmogorova-Smirnova and Shapiro-Wilk tests.  A significant 
result (p<0.05) indicates a non-normal distribution. The data was determined to be 
non-parametric based on its skewness and kurtosis (Table 4).   
 
A Chi Square analysis was conducted to determine if there was any association 
between categorical data in the datasets i.e. gender and a Charlson co-morbidity of 
zero and instances of PIP as defined by Beers and STOPP for residents in both 
jurisdictions.  
 
Mann Whitney U tests were performed to measure if there was any significant 
difference between median values in the number of medicines (including and 
excluding prn medicines) and the number of PIMs in both jurisdictions.  A one-tailed 
Spearman’s rho correlation coefficient test was performed to determine if there was 
any correlation between the dependent and independent variables e.g. number of 
medicines prescribed, gender, age and the occurrence of PIP.  A p value of <0.05 
was deemed to be significant. 
 
Table 4 Skewness and kurtosis of the datasets 
 Kolmogorov-Smirnov Shapiro-Wilk 
 Statistic Df p Statistic Df p 
Age 0.062 630 0.000 0.986 630 0.000 
       
       
       
df: Degrees of freedom 
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4.0 Results  
4.1 Demographics 
The total number of residents in the study was 630, 315 residents from both 
jurisdictions. The median age of the entire resident dataset was 84 (IQR: 78-89).  
The 80-84 year old category had the highest proportion of residents (27.3%), 
followed by the 85-89 year old category (24.4%). T here was an equal number of 
male and female residents in the 70-74 age category. There were more males than 
females in the 65-69 age category and for all the other age categories there were 
more females than males ( 
Figure 1).  The gender distribution in the matched datasets was female 74.9% and 
male 25.1%. 
 
 
 
 
Figure 1 Population and gender distribution by age category. 
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Table 5 Demographics of the age and gender matched combine datasets 
Demographics RoI Dataset 
(n=315) 
NI Dataset 
(n=315) 
Matched Dataset 
(n=630) 
Male 79 (25.1%) 79 (25.1%) 158 (25.1%) 
Female 236 (74.9%) 236 (74.9%) 472 (74.9%) 
Age Mean* 83.42 83.42 83.42 
Age Range* 65-99 65-99 65-99 
Age SD* ±7.048 ±7.048 ±7.048 
No. of medicines prescribed 
No. of regular medicines 
prescribed 
No. of “prn” medicines 
prescribed 
3,730 
 
2,683 
 
1,047 
3,394 
 
2,246 
 
1,148 
7,124 
 
4,929 
 
2,195 
Median number of medicines 
prescribed 
11 10 11 
Min-Max of medicines 
prescribed 
2-25 1-26 1-26 
IQR of medicines prescribed 9-14 7-13 8-14 
Mean of medicines prescribed 11.84 10.77 11.31 
    
Median number of regular 
medicines 
8 7 8 
Min-Max of regular medicines 1-19 0-20 0-20 
IQR of regular medicines 6-10 5-9 5-10 
Mean of regular medicines 8.52 7.13 7.82 
*Calculated in years 
 
4.2 Number of medications prescribed 
A total of 7,124 medicines were prescribed between the two datasets with 3,730 
medications being prescribed in the RoI dataset, and 3,394 medications being 
prescribed in the NI dataset.  The overall median number of medications per resident 
for the combined datasets was 11 (IQR 8-14), and the median number of 
medications per resident for the RoI dataset was 11 (IQR 9-13) and for the NI 
dataset was 10 (IQR 7-13). 
 
The main differences in the median number of medicines prescribed per age 
category between the two datasets was for the 80-84 years age category, where the 
median number of medicines prescribed for the RoI dataset was 12 and for the NI 
dataset was 10; in the 85-89 years age category the median number of medicines for 
the RoI dataset was 12 and for the NI was 10 and in the 90-94 years age category 
the median number of medications was 10 for the RoI dataset and 9 for the NI 
dataset ( 
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Figure 2) 
 
A Mann-Whitney U test revealed that there was a small significant difference, 
(p=<0.05) although somewhat small, between the number of medications from the 
RoI dataset (Md=11, n=315) and NI dataset (Md=10, n=315), U= 41,605, z=-3.515, 
p=0.000, r=0.14. 
 
 
Figure 2 Median number of medicines prescribed by age category for both 
datasets 
 
A Spearman’s rho correlation test found that in the RoI dataset there was a 
significant negative correlation between the age and the number of medications that 
residents in this dataset were prescribed i.e. as age increased the number of 
medications decreases (rs=-0.125, p<0.05).  Also as expected a significant positive 
correlation was also found for the Charlson co-morbidity index (CCI) score and the 
number of medications prescribed (rs=0.112, p<0.05).  Similarly in the NI dataset a 
negative correlation was found between the number of medications a resident 
received and age, but this was not found to be significant (rs= -0.079 p=0.164).  
There was also a significant correlation between the CCI score and the number of 
medications (rs= 0.146 p<0.05) (Table 6).   
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Table 6 Correlations between demographic variables and the number of 
medications that residents from both datasets were prescribed 
 
 
 
Age 
 
Female Gender 
 
CCI score 
 
Number of medications in the RoI dataset 
 
rs=--0.125 
p<0.05 
 
rs=0.042 
p=0.457 
 
rs=0.112 
p<0.05 
Number of medications in the NI dataset  rs=-0.079 
p=0.164 
rs=0.107 
p=0.059 
rs=0.146 
p<0.05 
Key: CCI: Charlson Comorbidity Index  
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4.3 Medicines prescribed by physiological system 
As shown in Figure 3, the highest percentage of medicines prescribed for the entire 
dataset (29.7%) was for the Central Nervous System (CNS), as well as being the 
highest percentage of medicines prescribed within each individual dataset.  A higher 
percentage of CNS medicines was prescribed for residents from the RoI dataset 
than for residents from the NI dataset (RoI: 32.6%, NI: 26.5%).  
 
Medications classified by the World Health Organisation (ATC code) for the 
alimentary tract (AT) and metabolism system were the second most commonly 
prescribed category of medicines (23.5%) across the entire dataset, with a higher 
percentage of medicines from this class being prescribed in the RoI dataset 
compared to NI dataset (RoI: 24% and NI: 22.9%). 
 
Residents from RoI dataset also received a higher percentage of prescriptions 
written for medicines for the genito-urinary system (RoI: 1.6% and NI: 0.9%), 
respiratory system (RoI: 6.0% and NI: 5.7%) and the anti-infective drug category 
(RoI: 1.4% and NI: 0.8%) respectively. 
 
Residents from the NI dataset received a higher percentage of prescriptions written 
for medicines for the cardiovascular system (CVS) (RoI: 12.9% and NI: 15.1%), 
muscle-skeletal (MS) system (RoI: 2.5% and NI: 3.6%), medicines for the blood and 
for blood forming organs category (RoI: 6.8% and NI: 7.8%) and dermatological 
products (RoI: 3.7% and NI: 6.3%).  An equal percentage of medicines from the 
systemic hormone drug category (RoI: 1.9% and NI: 1.9%) was prescribed in each 
dataset (Figure 3).  
4.4 Medicines prescribed for the CNS 
Figure 4 illustrates the percentage of the medicines prescribed for each class of CNS 
medicines of the total CNS medicines prescribed to the entire dataset.  The RoI 
dataset had a higher percentage of analgesic agents prescribed compared to the NI 
dataset: (RoI: 26.3% and NI:  24.0%).  
 
A higher percentage of antidepressants (RoI: 14.6% and NI: 17.8%), hypnotics (RoI: 
12.6% and NI: 17.3%) was prescribed in the NI dataset compared to the RoI dataset. 
Conversely, a higher percentage of antipsychotics (RoI: 13.7 % and NI: 11.5%), 
opioids (RoI: 9.7% and NI: 9.32%) and anxiolytics (RoI: 11.3% and NI: 9.8%) was 
prescribed in the residents from the RoI dataset over the NI dataset.  A higher 
percentage of anti-epileptics (RoI: 5.4% and NI 3.4%) was prescribed in the RoI 
dataset when compared to the NI dataset.  
 
There was a higher percentage of dopaminergic agents (RoI: 3.0% and NI 3.3%) and 
anti-dementia type agents (RoI: 1.8% and NI 2.4%) prescribed in the NI dataset 
compared to the RoI dataset.  There was no difference in the percentage of 
anticholinergic agents prescribed across both datasets (RoI: 0.4% and NI 0.4%).  
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Figure 3 Contribution (%) of each physiological system to the overall 
prescribing both as a total usage and within each dataset 
 
 
Figure 4 Percentage (%) of each individual class of medicines to the overall 
prescribing within the CNS  
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4.5 Medicines prescribed for the alimentary tract (AT) and metabolism 
Figure 5 below illustrates the breakdown of the medicines prescribed for each class 
of medicine as per alimentary (AT) and metabolic drug class, as a percentage of the 
total metabolic and AT medicines prescribed to the entire dataset and in each 
individual dataset. 
 
 
Figure 5 Percentage of medicines prescribed as per the alimentary and 
metabolic ATC codes, both as a total usage and within each dataset. 
 
A higher percentage of laxatives (RoI: 53.7% and NI: 44.5%), propulsives (RoI: 5.6% 
and NI: 2.1%) and belladonna type medicines and their derivatives (RoI: 1.5% and 
NI: 0.8%) was prescribed in the RoI dataset in comparison to the NI dataset.  
 
A higher percentage of medicines for gastro-oesphageal reflux disorders and peptic 
ulcer disease (RoI: 20.5% and NI: 24.0%), anti-propulsives (RoI: 1.7% and NI: 
3.0%), calcium containing agents (RoI: 6.1% and NI: 8.4%), blood glucose lowering 
agents (RoI: 4.5% and NI: 4.9%), insulin and its analogues (RoI: 1.1% and NI: 1.8%) 
and vitamin C containing combinations (RoI: 0.8% and NI: 1.4%) was prescribed in 
the NI dataset  compared to the RoI dataset.  There was very little difference in the 
percentage of stomatological preparations (RoI: 0.9% and NI: 0.7%) prescribed 
between the two datasets (Figure 5).  
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4.6 Medicines prescribed for the CVS 
Figure 6 illustrates the breakdown of the medicines prescribed for each class of CVS 
medicines, as a percentage of the total CVS medicines prescribed to the entire 
dataset and in each individual dataset. 
 
 
Figure 6 Percentage (%) of medicines prescribed as per the CVS ATC codes, 
both as a total usage and within each dataset. 
 
Slightly more high ceiling type diuretics (RoI: 19.7% and NI: 20.0%) were prescribed 
in the NI dataset compared to the RoI dataset. 
 
A higher percentage of β blockers (RoI: 15.8% and NI: 12.3%) and lipid modifying 
agents (RoI: 14.1% and NI: 11.7%) was prescribed in the RoI dataset in comparison 
with the NI dataset. 
 
There was very little difference in the percentage of Angiotension 2 inhibitors (RoI: 
11.0% and NI: 11.4%). 
 
A higher percentage of cardiac glycosides (RoI: 7.3% and NI: 6.7%), calcium 
channel blockers (RoI: 5.6% and NI: 4.1%) and thiazide diuretics (RoI: 2.5% and NI: 
5.1%) was prescribed in the NI dataset when compared with the RoI dataset. 
 
A significantly higher percentage of vasodilator agents used for cardiac disease was 
prescribed in the NI dataset compared to RoI (RoI: 3.9% and NI: 15.3%). 
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A higher percentage of agents for the treatment of haemorrhoids and related agents 
was prescribed in the NI dataset in comparison to the RoI dataset (RoI: 2.1% and NI: 
3.9%).  
4.7 Medicines prescribed for the blood and for blood forming organs as 
per ATC classification system 
A higher percentage of iron preparations (RoI: 15.7% and NI: 24.2%) was prescribed 
in the NI Irish dataset, whereas a higher percentage of vitamin B12 and folic acid 
type preparations (RoI: 20.8% and NI: 10.9%) was prescribed in the RoI Irish dataset 
over the NI Irish dataset. 
 
There was very little difference in the percentage of irrigation solution (RoI: 0.4% and 
NI: 1.1%) and antifibrinolytic agents (RoI: 11.0% and NI: 11.4%) prescribed between 
the two datasets.  Approximately the same percentage of antithrombotic agents (RoI: 
63.5% and NI: 63.8%) was prescribed in both the NI and RoI datasets (
 
 
Figure 7). 
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Figure 7 Percentage (%) of medicine prescribed as per the blood and for blood 
forming organs ATC codes, both as a total usage and within each dataset. 
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4.8 Medicine prescribed for the Respiratory System 
A higher percentage of decongestants and nasal preparations (RoI: 38.7% and NI: 
35.9%), adrenergics inhaler (RoI: 16.7% and NI: 0.5%) and systemic adrenergics 
(RoI: 4.5% and NI: 1.6%) was prescribed in the RoI dataset than in the NI dataset.  
 
Whereas a higher percentage of systemic antihistamines (RoI: 0.5% and NI: 1.4%), 
throat preparations (RoI: 14.4% and NI: 15.1%), cough suppressants (RoI: 0% and 
NI: 2.1%), expectorants (RoI: 1.4% and NI: 2.7%), other miscellaneous systemic 
agents for obstructive airway diseases (RoI: 2.7% and NI: 3.1%), inhaled agents for 
the treatment of obstructive airways disease (RoI: 2.7% and NI: 4.2%) and systemic 
nasal decongestants (RoI: 18.5% and NI: 33.9%) was prescribed in the NI dataset 
than in the RoI dataset (
 
Figure 8). 
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Figure 8 Percentage (%) of each of the medicines for the Respiratory system 
prescribed to the overall prescribing of these medicines, both as a total usage 
and within each dataset. 
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4.9 Medicines prescribed for dermatological conditions  
A higher percentage of topical antifungal preparations (RoI: 21.7% and NI: 10.8%), 
topical corticosteroids based preparations (RoI: 17.4% and NI: 7.5%), topical anti-
psoriatic preparations (RoI: 2.9% and NI: 1.4%), topical corticosteroid combination 
preparations (RoI: 3.6% and NI: 3.3%) and preparations from the other 
miscellaneous dermatological preparation category (RoI: 22.5% and NI: 4.7%) was 
prescribed in the RoI dataset than in the NI dataset.  
 
Whereas in the NI dataset a higher percentage of topical anti-pruritics (RoI: 2.2% 
and NI: 2.8%), topical antibiotics (RoI: 2.2% and NI: 4.2%), topical antibiotic–
corticosteroid based preparations (RoI: 0.7% and NI: 4.2%), topical antiseptic–
corticosteroid based preparations (RoI: 1.5% and NI: 13.6%), and emollients and 
protective type preparations (RoI: 25.4% and NI: 42.3%) was prescribed than in the 
RoI dataset (
 
Figure 9)  
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Figure 9 Percentage (%) of each of the medicines for dermatological 
conditions prescribed to the overall prescribing of these medicines, both as a 
total usage and within each dataset. 
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4.10 Co-morbidity data in combined datasets 
The Charlson Co-morbidity Index (CCI) scores were calculated for all study 
participants and were found to be consistent across each dataset, with less than 
20% of residents in each dataset not scoring on the CCI index, indicating the relative 
frailty and high incidence of chronic illness in this patient population (Table 7).  Chi 
Square analysis did not reveal any significant association between the gender of 
residents in each dataset that scored zero on the CCI index (χ2= 2.246, p= 0.134).  
 
Table 7 CCI of the entire dataset and each individual dataset 
CCI NI Dataset 
(n=315) 
RoI Dataset 
(n=315) 
Total 
(n=630) 
 
CCI 0 
Male:Female 
 
50 (15.87) 
17:33 
 
39 (12.38) 
11:28 
 
89 (14.13) 
28:61 
 
CCI 1 
Male:Female 
 
126 (40.00) 
30:96 
 
97 (30.79) 
28:73 
 
123 (19.52) 
58:169 
 
CCI 2 
Male:Female 
 
91 (28.89) 
21:70 
 
64 (20.32) 
19:45 
 
155 (24.60) 
40:115 
 
CCI 3 
Male:Female 
 
29 (9.21) 
3:26 
 
65 (20.63) 
14:51 
 
94 (14.92) 
17:77 
 
CCI 4 
Male:Female 
 
11 (3.49) 
5:6 
 
31 (9.84) 
7:24 
 
42 (6.67) 
12:30 
 
CCI 5 
Male:Female 
 
8 (2.54) 
3:5 
 
13 (4.13) 
4:9 
 
21 (3.33) 
7:14 
 
CCI 6 
Male:Female 
 
- 
 
5 (1.59) 
0:5 
 
5 (0.79) 
0:5 
 
CCI 7 
Male:Female 
 
 
 
1 (0.32) 
0:1 
 
1 (0.16) 
0:1 
Key: CCI: Charlson Comorbidity Index 
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4.11 Prevalence of PIP measured per dataset as defined by the Beers 
and STOPP criteria 
Table 8 below summarises the rates of PIP including and excluding as required “prn” 
when the Beers’ criteria were applied to residents’ information for each dataset.  
 
A Chi-square test for independence indicated that there was a significant association 
between the jurisdictions and the occurrence of PIP as defined by the Beers’ criteria 
when instances of PIP relating to “prn” medications were excluded (χ2=28.558, 
p<0.05) but when “prn” medicines were included an association was not reported 
(χ2=0.411, p=0.521).  An association between the rate of PIP obtained for the 
application of the STOPP criteria and locality was found but it was reported not to be 
significant when “prn” medicines were included (χ2=2.729, p= 0.099) or when the 
instances of PIP relating to “prn” medicines were removed (χ2=2.459, p= 0.117). 
 
Table 8 below outlines the rate of PIP per dataset and it includes both the 
prevalence of PIP for both datasets including and excluding “prn” medicines. In the 
NI dataset the PIP prevalence reported for the Beers criteria was 56.8% (48.6% 
excluding “prn” medicine) and the PIP prevalence reported for STOPP in the NI 
dataset was 67.0% (60.0% excluding “prn” medicines). In the RoI dataset the PIP 
prevalence reported for the Beers criteria was 54.3% (41.6% excluding “prn” 
medicine) and the PIP prevalence rate identified by STOPP reported for the RoI 
dataset was 73.0% (66.0% excluding “prn” medicines) (Table 8). 
 
Table 8 The rates of PIP calculated per dataset 
  
NI Dataset 
 
RoI Dataset 
 
Beers’ Criteria (%) 
 
 
56.8% 
 
54.3% 
 
Beers’ criteria excluding prn medicines (%) 
 
 
48.6% 
 
41.6% 
 
STOPP Criteria (%) 
 
 
67.0% 
 
73.0% 
 
STOPP Criteria excluding prn medicines (%) 
 
 
60.0% 
 
66.0% 
 
4.11.1 Application of the Beers’ criteria to the Northern Irish and 
Republic of Ireland datasets 
When the Beers’ criteria were applied to the patient profiles of the residents in the 
RoI dataset they identified 384 instances of potential inappropriate prescribing (PIP) 
relating to 259 PIMs (108 independent of diagnosis (ID) and 276 considering 
diagnosis (CD) in a total of 171 (54.3%) residents when “prn” type medications were 
included and 275 (74 ID and 201 CD) instances of PIP relating to 180 PIMs in 131 
residents (41.6%) when instances of PIP relating to “prn” type medicines were 
excluded.  In the RoI dataset more males had one or more instances of PIP (62.0%) 
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compared to the female population (51.7%); this trend remained constant even after 
the instances of PIP relating to “prn” medicines were removed (46.8% of males and 
39.8% of females respectively) (Table 9).  
 
Sixty nine (21.9%) residents had one instance of PIP prescribed, forty five (14.3%) 
residents had two instances of PIP and fifty seven (18.1%) residents had three or 
more instances of PIP. When prn medicines were removed fifty nine (18.7%) 
residents had one instances of PIP, thirty four (10.8%) had two, thirty eight (12.1%) 
had three or more instances of PIP (Table 9). 
 
Table 9 Number of residents with instances of PIPs identified by Beers’ criteria 
in the RoI dataset 
Number of 
PIP 
instances 
Male 
(n=79) 
Female 
(n=236) 
Total (%) 
(n=315) 
Male ex 
prn PIMs 
(n=79) 
Female ex. 
Prn PIMs 
(n=236) 
Total ex prn 
PIMs (%) 
(n=315) 
1 21 (26.6) 48 (20.3) 69 (21.9) 17 (21.5) 42 (17.8) 59 (18.7) 
2 14 (17.7) 31 (13.1) 45 (14.3) 13 (16.5) 21 (8.9) 34 (10.8) 
≥3 14 (17.7)  43 (18.2) 57 (18.1) 7 (8.9) 31 (13.1) 38 (12.1) 
 
Total 
Residents 
 
49 (62.0) 
 
122 (51.6) 
 
171 (54.3) 
 
37 (46.9) 
 
94 (39.8) 
 
131 (41.6) 
 
Total PIP 
instances 
   
384 
 
   
275 
 
 
When the Beers’ criteria were applied to the NI resident profiles they identified 381 
instances of PIP (183 ID and 198 CD) relating to 265 PIMs in a total of 179 (56.8%) 
residents.  When the instances of PIP relating to “prn” medicines were removed it 
resulted in 283 instances of PIP (136 ID and 147 CD) relating to 204 PIMs in 153 
(48.5%) residents.  
 
Sixty nine (21.9%) residents had one instance of PIP prescribed, 58 (18.4%) had two 
and 38 (16.5%) residents had three or more instances of PIP. When “prn” medicines 
were removed 74 (23.5%) residents had one instance of PIP, 48 (15.2%) had two, 
31 (9.8%) had three or more instances of PIP (Table 10). 
 
Table 10 Number of residents with instances of PIPs identified by Beers’ 
criteria in the NI dataset 
Number 
of PIP 
instances 
Male 
(n=79) 
Female 
(n=236) 
Total (%) 
(n=315) 
Male ex 
prn PIMs 
(n=79) 
Female ex. 
Prn PIMs 
(n=236) 
Total ex prn 
PIMs (%) 
(n=315) 
1 18 (22.8) 51 (21.6) 69 (21.9) 20 (25.3) 54 (22.9) 74 (23.5) 
2 12 (15.2) 46 (19.5) 58 (18.4) 10 (12.7) 38 (16.1) 48 (15.2) 
≥3 14 (17.7) 38 (16.1) 52 (16.5) 8 (10.1) 23 (9.7) 31 (9.8) 
Total 
Residents 
44 (55.7) 135 (57.2) 179 (56.8) 38 (48.1) 115 (48.7) 153 (48.5) 
 
Total PIP 
instances 
   
381 
 
   
283 
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Overall, only 28 (12 CD and 16 ID) of the 68 Beers’ criteria (41.2%) were used to 
identify these instances of PIP including “prn” medicines in the RoI dataset and 26 
(12 CD and 14 ID) (Table 11-12) of the 68 Beers’ criteria (38.2%) when “prn” 
medicines were excluded.  In the NI dataset 26 (7 CD and 19 ID) of the 68 Beers’ 
criteria (38.2%) were utilised to identify instances of PIP when “prn” medicines were 
included and excluded. 
 
In the RoI dataset prescribing of benzodiazepines accounted for 51 (47.2%) of the 
inappropriate medicines identified by the Beers’ ID criteria when “prn” medicines 
were included and accounted for 34 (45.9%) when “prn” medicines were excluded. In 
the NI dataset the prescribing of benzodiazepines accounted for 84 (45.9%) of the 
inappropriate medicines identified by the Beers’ ID criteria when “prn” medicines 
were included and accounted for 45 (33.1%) when “prn” medicines were excluded. 
 
Fluoxetine was prescribed on 5 occasions (1.6% of residents) in the RoI dataset and 
accounting for 4.6% (6.8% excluding “prn” medicines) of the total instances of PIP 
identified by Beers’ ID criteria but was prescribed on 31 occasions (9.8% of 
residents) in the NI dataset and accounted for 16.9% (22.8% excluding “prn” 
medicines) of total instances of PIP identified by Beers’ ID criteria.  
 
In the RoI dataset a total of 276 instances of PIP (201 instances excluding “prn”) and 
in the NI dataset a total of 198 instances of PIP (147 instances excluding “prn”) were 
identified using Beers’ CD.  In both datasets the highest proportion were 
benzodiazepines in residents with a history of concurrent falls, in the RoI dataset 95 
(34.4%) instances of PIP were identified when “prn” medicines were included and 54 
(26.9%) instances of PIP when “prn” medicines were excluded. In the NI dataset 
residents using benzodiazepines with a history of concomitant falls was also the 
most prominent reason for PIP in the Beers CD list with 107 (54.0%) instances of 
PIP being identified when “prn” medicines were included and 73 (49.7%) instances 
of PIP identified when “prn” medicines are excluded. When the Beers’ ID and CD 
were combined, instances of PIP relating to benzodiazepines accounted for 38.0% 
(32.0% excluding “prn” medicines) of the total instances of PIP identified in the RoI 
dataset and 50.1% (41.7% excluding “prn” medicines) in the NI dataset (Table 11-
12). 
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Table 11 The instances of PIP identified by Beers’ criteria independent of 
diagnosis 
 
Medication 
 
 
Total 
RoI  PIP 
 
Total 
RoI PIP 
ex prn 
 
Total 
NI PIP 
 
Total  NI 
PIP ex 
prn 
Independent of Diagnosis     
Oxybutynin (unless XL) 2 2 2 2 
Flurazepam 9 9   
Amitriptyline 9 9 14 13 
Doxepin 1 1 1 1 
Short acting benzodiazepines: (Doses >)     
Lorazepam 3mg     
Temazepam 5 5 16 15 
Triazolam     
Long Acting benzodiazepines:     
Chlordiazepoxide     
Diazepam 35 18 68 30 
Long-acting benzodiazepines 2 2   
Disopyramide 1  4 4 
Digoxin   2 2 
Belladonna alkaloids 13 3 5 5 
Chlorpheniramine 8 3 19 13 
Diphenhydramine     
Promethazine   3 3 
Hydroxyzine   1 1 
All barbiturates (except Phenobarbital) except when 
used to control seizures 
  1 1 
Long term long t1/2 NSAIDs: Naproxen   1 1 
Fluoxetine 5 5 31 31 
Bisacodyl 1  2 2 
Amiodarone 5 5 7 6 
Nitrofurantoin 7 7 2 2 
Doxazosin 4 4 3 3 
Estrogen 1 1 1 1 
     
Total Independent of Diagnosis 
 
108 74 183 136 
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Table 12 The instances of PIP identified by Beers’ criteria considering 
diagnosis 
Key: >: Greater than, t1/2: half life, NSAIDs: Non-Steroidal Anti-Inflammatory Drugs, COPD: Chronic 
Obstructive Pulmonary Disease, CCBs: Calcium Channel Blockers, TCAs: Tricyclic Antidepressants 
Medication 
 
Total RoI 
PIP 
Total RoI 
PIP ex prn 
Total NI 
PIP 
Total NI PIP 
ex prn 
Considering Diagnosis     
Heart failure     
High sodium content medicines     
Peptic ulcer disease     
NSAIDs 7 4   
Blood clotting disorder     
NSAID 1 0   
Asprin 1 1   
Dipyridamole 1 1   
Clopidogrel 1 1   
Bladder outflow obstruction     
Anticholinergics 3 1 2 1 
Antidepressants 5 5 3 3 
Muscle relaxants 4 3   
Stress Incontinence     
TCAs 7 7 1 1 
Benzodiazepine 12 7 4 2 
Anticholinergics 10 7 2 2 
Alpha blockers 7 7   
Arrhythmia     
TCA 1 1   
Parkinsons Disease     
Conventional Antipsychotics 3 3   
Cognitive Impairment     
Muscle relaxants 5 4 1 1 
Anticholinergics 19 11 27 19 
Barbiturates   1 1 
Depression     
Long term benzodiazepine 44 44 22 22 
Fall & Syncope     
Benzodiazepines 95 54 107 73 
TCAs 5 5 20 18 
Obesity     
Olanzapine 1 1   
COPD     
Long acting benzodiazepines 4 3 6 2 
β-blocker: propranolol   1 1 
Constipation     
CCBs 11 11 1 1 
TCAs 7 7   
Anticholinergics 22 13   
Total Considering Diagnosis 276 201 198 147 
Total Independent of Diagnosis & 
Considering Diagnosis 
 
384 
 
275 
 
381 
 
283 
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4.11.2 The application of the STOPP criteria to both datasets 
In the RoI dataset the STOPP criteria identified a total of 568 instances of PIP 
relating to 500 PIMs in 230 (73.0%) residents when “prn” medicines were included 
and 429 instances of PIP relating to 375 PIMs in 208 (66.0%) residents when “prn” 
were excluded. Eighty seven residents (27.6%) had one instance of PIP, 59 (18.7%) 
residents had two instances of PIP and 84 (26.7%) residents had three or more 
instances of PIP. When instances of PIP relating to “prn” medicines were removed 
96 (30.5%) residents had one instance of PIP 60 (19.0%) residents had two 
instances of PIP and 52 (16.5%) residents had three or more instances of PIP. 
 
In the NI dataset STOPP identified a total of 478 instances of PIP relating to 420 
PIMs in 211 (67.0%) residents when “prn” medicines were included and 356 
instances of PIP relating to 298 PIMs in 189 (60.0%) residents when instances of 
PIP relating to “prn” were removed. Eighty six residents (27.3%) residents had one 
instance of PIP, 56 (17.8%) residents had two instances of PIP and 69 (21.9%) 
residents had three or more instances of PIP. 
 
When instances of PIP relating to “prn” medicines were removed, 97 patients 
(30.8%) had one instance of PIP, 48 (15.2%) patients had two instances of PIP and 
44 (14.0%) patients had three or more instances of PIP. 
 
In the RoI dataset slightly more of the male population were prescribed one or more 
instances of PIP (78.5%) than the female population (71.2%); this trend remained 
constant even after the instances of PIP relating to “prn” medicines were removed 
72.2% of males and 63.9% of females being prescribed one or more instances of 
PIP (  
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Table 13).  
 
Whereas in the NI dataset slightly more females (67.4%) were prescribed one or 
more instances of PIP than the male population (65.8%) when the “prn” medicines 
were included but when instances of PIP relating to “prn” medicines were removed 
more males (62.0%) than females (59.3%) appeared to be prescribed one or more 
instances of PIP (Table 14). 
 
A Mann-Whitney U test showed that there was no statistically significant difference 
between the number of instances of PIP identified by STOPP for each resident 
between the two datasets (z=-1.892, p=.058) 
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Table 13 The number of residents from RoI dataset with instances of PIP 
identified by STOPP 
Number 
of PIP 
instances 
Male 
(n=79) 
Female 
(n=236) 
Total (%) 
(n=315) 
Male ex 
prn PIMs 
(n=79) 
Female ex. 
Prn PIMs 
(n=236) 
Total ex prn 
PIMs (%) 
(n=315) 
1 28 (35.4) 59 (25.0) 87 (27.6) 27 (34.2) 69 (29.2) 96 (30.5) 
2 14 (17.7) 45 (19.1) 59 (18.7) 18 (22.8) 42 (17.8) 60 (19.0) 
≥3 20(25.3) 64 (27.1) 84 (26.7) 12 (15.2) 40 (16.9) 52 (16.5) 
 
Total 
residents 
 
62 (78.5) 
 
168 (71.2) 
 
230 (73.0) 
 
57 (72.2) 
 
151 (63.9) 
 
208  (66.0) 
Total PIP 
instances 
  568   429 
 
Table 14 The number of residents from NI dataset with instances of PIP 
identified by STOPP 
Number 
of PIP 
instances 
Male 
(n=79) 
Female 
(n=236) 
Total (%) 
(n=315) 
Male ex 
prn PIMs 
(n=79) 
Female ex. 
Prn PIMs 
(n=236) 
Total ex prn 
PIMs (%) 
(n=315) 
1 24  (30.4) 62 (26.3) 86 (27.3) 25 (31.6) 72 (30.5) 97 (30.8) 
2 13 (16.4) 43 (18.2) 56 (17.8) 15 (19.0) 33 (14.0) 48 (15.2) 
≥3 15 (19.0) 54 (22.9) 69 (21.9) 9 (11.4) 35 (14.8) 44 (14.0) 
 
Total 
residents 
 
52 (65.8) 
 
159 (67.4) 
 
211 (67.0) 
 
49 (62.0) 
 
140 (59.3) 
 
189  (60.0) 
Total PIP 
instances 
  478 
 
  356 
 
 
In the RoI dataset, of the 65 criteria in STOPP, 39 (60.0%) were used to identify PIP 
whereas in the NI dataset only 30 (46.15%) of the 65 criteria were used.  The highest 
prevalence of PIP in the RoI and NI datasets relates to STOPP criterion H: “Drugs 
that adversely affect fallers” n=143 and n=189 respectively.  This was followed by 
medicines whose primary effect was on the central nervous system (CNS) in the RoI 
dataset n=143 and in the NI dataset n=91 (Figure 10). Prescribing of duplicate drug 
classes accounted for a total of 29 PIMs, the endocrine system accounted for six and 
only one IP was identified for the respiratory system (  
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Table 15). 
 
 
 
Figure 10 The instance of PIP per physiological system.  
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Table 15 The number of instances of PIP identified by the STOPP criteria in the 
RoI and NI datasets. 
CRITERIA RoI Total RoI Total 
ex “prn” 
medicines 
NI Total NI Total 
ex “prn” 
medicines 
Cardiovascular System     
Loop diuretic & ankle oedema 
Loop diuretic 1st line for hypertension 
CCBs & constipation 
beta-blocker & COPD 
Aspirin >150mg daily 
Aspirin: not indicated 
Diltiazem or verapamil &Class III or IV 
heart failure 
5 
10 
11 
 
 
9 
1 
5 
10 
11 
 
 
9 
1 
 
3 
3 
 
1 
1 
16 
 
 
3 
3 
 
1 
1 
16 
 
 
Central Nervous System     
TCAs & dementia  
TCAs & cardiac conductive 
abnormalities 
TCAs & constipation 
TCAs & opiate or CCB 
TCA & prostatism  
Long term long half life 
benzodiazepine  
Neuroleptics as long-term hypnotics 
i.e. > 1 month  
Neuroleptics in Parkinsons Disease  
Phenothiazines & epilepsy 
Anticholinergics for extra-pyramidal 
side effects 
>1 week 1st generation antihistamines 
3 
1 
6 
7 
 
 
29 
13 
 
16 
2 
5 
9 
3 
1 
6 
5 
 
 
29 
13 
 
15 
1 
5 
9 
4 
2 
 
19 
1 
 
32 
29 
 
4 
 
1 
22 
4 
2 
 
5 
1 
 
32 
22 
 
2 
 
1 
22 
Respiratory System 
Theophylline monotherapy for COPD 
Systemic corticosteroids instead of 
inhaled for COPD 
 
2 
 
 
 
2 
 
 
 
1 
 
 
1 
Nebulised ipratropium with glaucoma 1 1   
Gastro Intestinal System     
Diphenoxylate/ codeine phosphate for 
chronic diarrhoea 
Diphenoxylate/ loperamide/ codeine 
phosphate for acute infective 
gastroenteritis 
Metoclopramide/ prochlorperazine & 
Parkinsonism  
PPI for PUD at full therapeutic dosage 
for > 8 weeks 
Anticholinergic antispasmodic & 
chronic constipation 
1 
 
 
 
 
2 
 
74 
 
4 
1 
 
 
 
 
1 
 
74 
 
 
 
 
 
 
 
 
66 
 
1 
 
 
 
 
 
 
 
66 
 
1 
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CRITERIA RoI Total RoI Total 
ex “prn” 
medicines 
NI Total NI Total 
ex “prn” 
medicines 
Musculoskeletal System     
NSAID & hypertension 
Long term continuous NSAID  for OA 
NSAID & Heart Failure 
Aspirin & Warfarin & NSAID 
NSAID & chronic renal impairment 
Long term corticosteroid (>3 months) as 
monotherapy for RA or OA 
30 
5 
7 
3 
1 
5 
 
15 
5 
1 
2 
1 
5 
 
4 
3 
2 
 
2 
3 
 
4 
3 
1 
 
2 
3 
 
Genitourinary System     
Bladder antimuscarinic drugs & 
dementia  
Antimuscarinic drugs & chronic 
glaucoma 
Antimuscarinic drugs & chronic 
constipation  
Antimuscarinic drugs & urinary outflow 
problems 
α-blockers in males & frequent 
incontinence  
α-blockers & long term urinary catheter 
in situ  
4 
 
1 
 
7 
 
7 
 
2 
4 
 
1 
 
7 
 
7 
 
2 
4 
 
1 
 
 
 
1 
4 
 
1 
 
 
 
1 
Falls     
Benzodiazepines  
Neuroleptic drugs  
1st generation antihistamines  
Long term opiates  
94 
57 
7 
31 
56 
52 
4 
31 
107 
55 
26 
16 
73 
45 
13 
16 
Analgesics     
Use of powerful opiate as 1st line 
therapy for mild-moderate pain  
Long term opiates in those with 
dementia 
1 
 
10 
1 
 
10 
1 
 
1 
 
Duplicate class 85 23 50 9 
 
Total PIMs  
 
568 
 
429 
 
478 
 
356 
Key: COPD: Chronic Obstructive Pulmonary Disease, CCBs= Calcium Channel 
Blockers, PPI: Proton Pump Inhibitor, PUD: Peptic Ulcer Disease, TCA: Tricyclic 
Antidepressant, OA: Osteoarthritis, NSAID: Non Steroidal Anti-inflammatory.  
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4.13 Variables associated with PIP in older residents 
In the RoI dataset a significant correlation was found between the number of 
medicines prescribed and the occurrence of PIP identified using Beers’ criteria (rs= 
0.372, p<0.01) and STOPP (rs=0.356, p<0.01) using Spearman’s rho correlation 
test.  There was also a significant correlation between being on more than five 
medicines (internationally accepted standard of polypharmacy) and the occurrence 
of PIP identified by the STOPP (rs= 0.135, p<0.01) criteria but not for the Beers’ 
criteria.  A negative correlation between age and CCI score and the occurrence of 
PIP using Beers’ criteria and STOPP  but this was found to be statistically non-
significant..  
Table 16. Demographic variables and the occurrence of PIP using Beers’ 
criteria, STOPP in the RoI dataset 
 
Republic 
of Ireland 
Dataset 
 
Age 
 
Female 
Gender 
 
No. of 
medicines 
prescribed 
 
CCI 
score 
 
>5 meds 
 
≥80 years 
 
PIP & 
STOPP 
 
 
rs=-0.023 
p=0.682 
 
rs=-0.071 
p=0.207 
 
rs=0.356 
p<0.01 
 
rs=-
0.050 
p=0.376 
 
rs=0.135 
p<0.05 
 
rs=-0.053 
p=0.347 
 
PIP & 
STOPP 
ex prn 
 
 
rs=-0.076 
p=0.176 
 
rs=-0.075 
p=0.186 
 
rs=0.292 
p<0.01 
 
rs=-
0.014 
p=0.803 
 
rs=0.010
0 
p=0.078 
 
rs=-0.005 
p=0.929 
 
PIP & 
Beers 
 
 
rs=-0.013 
p=0.814 
 
rs=-0.090 
p=0.111 
 
rs=0.372 
p<0.01 
 
rs=-
0.072 
p=0.201 
 
rs=0.052 
p=0.358 
 
rs=-0.046 
p=0.417 
 
PIP & 
Beers ex 
prn 
 
 
rs=-0.051 
p=0.367 
 
rs=-0.062 
p=0.276 
 
rs=0.318 
p<0.01 
 
rs=-
0.074 
p=0.193 
 
rs=0.006 
p=0.918 
 
rs=-0.006 
p=0.919 
Key: CCI: Charlsons Comorbidity Index 
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Similarly in the NI dataset there was a significant correlation found between the 
number of medicines prescribed and the occurrence of PIP identified using Beers’ 
criteria (rs= 0.376, p<0.01) and STOPP (rs=0.356, p<0.01) using Spearman’s rho 
correlation test.  There was also a significant correlation found between being on 
more than 5 medicines and the occurrence of PIP identified by the Beers’ (rs= 0.267, 
p<0.01) and STOPP (rs= 0.258, p<0.01) criteria.  There was also a significant 
correlation found between being female and the occurrence of PIP identified by the 
Beers’ (rs= 0.131, p<0.05) criteria, but this correlation was not found for PIP 
identified by the STOPP criteria.  Similar to the findings in the RoI dataset there was 
a negative correlation found between age and CCI score and the identification of PIP 
by Beers (rs= -0.45, p=0.426) and STOPP (rs= -0.034 p=0.551) but this was found to 
be statistically non-significant.  This negative correlation between PIP identified by 
the STOPP and Beers criteria could in part be due to the fact that younger elders 
were being prescribed more medicines (Table 17).   
 
Table 17 Demographic variables and the occurrence of PIP using Beers’ 
criteria, STOPP in the NI dataset 
 
Northern 
Irish 
Dataset 
 
 
Age 
 
Female 
Gender 
 
No. of 
medicines 
prescribed 
 
 
CCI 
score 
 
>5 meds 
 
≥80 
years 
 
PIP & 
STOPP 
 
 
rs= -0.034 
p=0.551 
 
rs= -0.011 
 p=0.207 
 
rs= 0.356 
p<0.01 
 
rs= -0.03 
p=0.376 
 
rs= -0.258 
p<0.01 
 
rs= -0.010 
p=0.863 
 
 
PIP & 
STOPP ex 
prn 
 
 
rs= -0.072 
p=0.203 
 
rs= -0.024 
p=0.672 
 
rs= 0.245 
p<0.01 
 
rs= -0.033 
p=0.555 
 
rs= -0.195 
p<0.05 
 
rs= -0.053 
p=0.352 
 
PIP & 
Beers 
 
 
rs= -0.045 
p=0.426 
 
rs= 0.131 
p<0.05 
 
rs= 0.376 
p<0.01 
 
rs= -0.74 
p=0.192 
 
rs= 0.267 
p<0.01 
 
rs= -0.42 
p=0.462 
 
 
PIP & 
Beers ex 
prn 
 
 
rs=-0.59 
p=0.300 
 
rs=-0.05 
p=0.927 
 
rs=0.267 
p<0.01 
 
rs=-0.033 
p=0.554 
 
rs=-0.220 
p<0.01 
 
rs=-0.012 
p=0.826 
Key: CCI: Charlson’s Comorbidity Index 
 
In the RoI dataset the number of instances of PIP identified was significantly lower 
using the Beers’ criteria than STOPP (Wilcoxon signed ranks test Z= -6.075; p<0.01) 
and in the NI dataset the number of instances of PIP identified was significantly 
lower using the Beers’ criteria than STOPP (Wilcoxon signed ranks test Z= -4.135; 
p<0.01).  
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4.14 The Net Ingredient Cost of PIP rates calculated per dataset 
The monthly net ingredient cost (NIC) for the PIMs identified by Beers in the NI 
dataset was £1,380.23 (€1,566.56) and when PIMs related to “prn” medicines were 
removed the NIC calculated was £1,314.58 (€1,492.05). The annual NIC for the 
PIMs identified by Beers in the NI dataset was £16,562.76 (€18,798.73) and the 
annual NIC when the PIMs relating to “prn” medicines were excluded was 
£15,774.96 (€17,904.58).  In the RoI dataset the NIC for the PIMs identified by Beers 
was €2,227.68 (£1,962.71) and when the PIMs relating to “prn” medicines were 
removed the NIC calculated was €2,160.02 (£1,903.10).  The annual NIC for the 
PIMs identified by Beers in the RoI dataset was €26,732.16 (£23,552.56) and the 
annual NIC when the PIMs related to “prn” medicines were excluded was €25,920.24 
(£22,837.22) (Table 18). 
 
The monthly NIC for the PIMs which were identified by STOPP in the NI dataset was 
calculated to be £3,953.28 (€4,486.98) and when PIMs relating to “prn” medicines 
were removed it was £3,237.89 (€3,675.01). T he annual NIC for the PIMs identified 
by STOPP in the NI dataset was £47,439.41 (€53,843.74) and the annual NIC when 
the PIMs related to “prn” medicines were excluded was £38854.68 (€44100.06).  
 
In the RoI dataset the NIC for PIMs identified by STOPP was €9,305.84 (£8,198.97) 
and when PIMs related to “prn” medicines were removed it was €8,644.33 
(£7,616.154) per month. The annual NIC for the PIMs identified by STOPP in the RoI 
dataset was €111,670.08 (£98,387.74) and the annual NIC when the PIMs related to 
“prn” medicines were excluded was €103,731.96 (£91,393.80) (Table 18). 
 
The overall combined annual total NIC for the entire dataset (RoI and NI combined) 
for PIMs identified by the Beers’ criteria was €45,530.89 (£40,115.32) and when 
“prn” related PIMs were excluded the total NIC was €43,824.82 (£38,612.18). The 
overall combined annual total NIC for the entire dataset (n=630) for PIMs identified 
by STOPP was €165,513.82 (£145,827.16) and when PIMs relating to “prn” 
medicines were excluded the annual total NIC calculated was €147,832.02 
(£130,248.48) (Table 18).    
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Table 18 The Net Ingredient Cost of PIM calculated per dataset 
  
NI 
Dataset 
 
Annual 
NI NIC 
 
RoI 
Dataset 
 
Annual RoI  
NIC 
 
Total Irish 
Monthly 
NIC 
 
Total 
annual Irish 
NIC 
NIC Beers’ 
criteria  
(€) 
(£) 
 
 
1,566.56 
1,380.23 
 
 
18,798.73 
16,562.76 
 
 
2,227.68 
1,962.71 
 
 
26,732.16 
23,552.56 
 
 
3,794.24 
3,342.94 
 
 
45,530.89 
40,115.32 
NIC Beers’ 
criteria 
excluding 
prn 
medicines  
(€) 
(£) 
 
 
 
 
 
1,492.05 
1,314.58 
 
 
 
 
 
17,904.58 
15,774.96 
 
 
 
 
 
2,160.02 
1,903.10 
 
 
 
 
 
25,920.24 
22,837.22 
 
 
 
 
 
3,652.07 
3,217.68 
 
 
 
 
 
43,824.82 
38,612.18 
NIC 
STOPP  
(€) 
(£) 
 
 
4,486.98 
3,953.28 
 
 
53,843.74 
47,439.41 
 
 
9,305.84 
8,198.97 
 
 
111,670.08 
98,387.74 
 
 
13,792.82 
12,152.26 
 
 
165,513.82 
145,827.16 
NIC 
STOPP 
excluding 
prn 
medicines  
(€) 
(£) 
 
 
 
 
 
3,675.01 
3,237.89 
 
 
 
 
 
44,100.06 
38,854.68 
 
 
 
 
 
8,644.33 
7,616.15 
 
 
 
 
 
 
103,731.96 
91,393.80 
 
 
 
 
 
12,319.34 
10,854.04 
 
 
 
 
 
 
147,832.02 
  130,248.48 
Key: NIC: Net Ingredient Cost  
The January 2010 exchange rate of 1.135 was used to calculate the price 
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5.0 Discussion 
Some of the general key findings from this study were: 
1. the positive correlations of residents from both datasets being prescribed 
multiple medicines and the occurrence of PIPs as defined by both the STOPP 
and the Beers’ criteria;  
2. a negative correlation between the age of a resident (in both datasets) and their 
CCI score and the occurrence of PIP as defined by both criteria;  
3.  a positive correlation in the NI dataset between the female gender and the 
occurrence of PIPs as defined by the Beers’ criteria (not observed in the RoI 
dataset with either set of criteria nor with the STOPP criteria in the NI dataset).  
 
Key medicines / medication classes implicated as PIMs in both datasets 
Inappropriate prescribing of long-acting benzodiazepines in older patients has been 
highlighted repeatedly in the literature over the last 25 years, in particular given the 
link with falls and fracture risk and the difficulties with successful withdrawal (Parr et 
al. 2008; Pimlott et al. 2003; Wang et al. 2001).  Despite this, long-acting 
benzodiazepines continue to be initiated and repeatedly prescribed for older patients 
in primary and secondary care in Ireland and other countries (de Oliveira Martins et 
al. 2006; de Wilde et al. 2007; Rajska-Neumann et al. 2007; Ryan et al. 2009; van 
der Hooft et al. 2005).  These realities suggest that long-acting benzodiazepines 
should not be initiated in older patients, given their high propensity for psychological 
and physical dependency (Chutka et al. 2004; Lader 1991; Mangoni et al. 2004; 
Turnheim 2003). Despite this, benzodiazepines were the most commonly occurring 
instances of PIP in both datasets i.e. the breached criteria related to the STOPP 
criteria H1- “use of benzodiazepines in individuals with a history of falls” (in the RoI 
n=97 and in the NI dataset n=107).  It has been widely documented that the use of 
benzodiazepines in individuals already predisposed to falls can further contribute to 
future falls.  This occurs primarily due to the CNS sedative effect of this class of 
medications but may also be due to their muscle relaxing properties, which can lead 
to weakening of the muscles of the lower back and upper legs, therefore directly 
affecting a resident’s stability.  This medication class can often prove quite 
problematic in older individuals who already exhibit a lower level of stability (Bourin 
et al. 2010; Cumming et al. 1998; Landi et al. 2005; Pariente et al. 2008; Ray et al. 
2000). 
 
Adverse effects relating to the inappropriate use of long term neuroleptics as 
hypnotics, as well as their use in individuals suffering from certain underlying 
conditions i.e. Parkinson’s disease has been widely documented in the literature as a 
significant problem especially in older individuals (Alexopoulos et al. 2004; Maixner 
et al. 1999; Ruths et al. 2003; Stevenson et al. 2010).  This class of medications 
contributed to a total of 177 PIP instances (88 in the RoI dataset and 89 in the NI 
dataset) as defined by the STOPP criteria.   
 
Neuroleptics, long acting anticholinergic and long term opioids have also been 
documented throughout the literature as quite problematic and contributing to falls / 
ADEs.  It is widely documented that specific medication classes are associated with 
an increased risk of falls and/ or related hip fractures (Lawlor et al. 2003; Masud et 
al. 2001; Passaro et al. 2000; Whooley et al. 1999; Woolcott et al. 2009).  In both 
datasets a high incidence of PIP relating to these medications was identified (Table 
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15). In general, medications or medication class which predisposes an already 
vulnerable patient group to further falls should be avoided whenever possible.  
 
A high incidence of PIP associated with the use of high dose proton pump inhibitors 
(PPIs) “criteria C4 as per STOPP” was also apparent in both datasets (n=74 in the 
RoI and n=66 in the NI dataset). It may be argued that long-term, high-dose PPI 
treatment in older people is relatively harmless in terms of ADEs and this may be 
true in practice.  However, a number of relatively rare but potentially important ADEs 
have been identified as being associated with this class of medications. Yang et al. 
found that long-term use of PPIs at high doses was associated with an increased risk 
of hip fracture, due to their interference with calcium absorption and bone resorption 
(Yang et al. 2006).  PPIs are also associated with an increased risk of infection with 
Clostridium difficile (Dial et al. 2005). The inappropriate use of long term PPIs is of 
global concern. In a review conducted by Forgacs et al., the authors stated that 64% 
of hospital inpatients in Australia, 33% of hospital inpatients in Ireland and 65% of 
hospital inpatients in the UK, were taking PPIs outside the countries’ licensed 
indication for the medication (Forgacs et al. 2008).  
 
Continuation of high-dose PPI treatment without clear indication is expensive and 
almost always unnecessary.  The surge in PPI prescribing in recent years is a cause 
of major budgetary concern.  Annual expenditure on unnecessary PPI treatment is 
estimated to be £100m within the National Health Service (NHS) in the UK, and £2bn 
globally (Forgacs et al. 2008).  In Ireland, annual expenditure on PPIs increased 
from approximately €8 million in 1995 to €64 million in 2002, accounting for over 
10% of the total expenditure on drugs funded by the Irish government in 2002 
(McGowan et al. 2005). In the current climate of major fiscal pressure on health 
resources, the overuse of PPIs becomes more relevant in terms of overall drug 
expenditure by governments globally.  
 
Comparison of the detection rates of PIP between each screening tool 
In the RoI dataset the number of instances of PIP identified by the Beers’ criteria was 
found to be significantly lower than with the STOPP criteria (Wilcoxon signed ranks 
test Z= -6.075; p<0.001) similarly in the NI dataset the Beers’ criteria identified a 
significantly lower number of instances of PIP compared to the STOPP criteria 
(Wilcoxon signed ranks test Z= -4.135; p<0.01).  The superiority of the STOPP 
criteria in identifying instances of PIP has previously been reported in both primary 
and secondary care settings (Gallagher et al. 2008; Ryan et al. 2009).  The STOPP 
and Beers’ criteria gave a level of detection which varied considerably.  In the RoI 
dataset, 60.0% of the STOPP (Section 4.11) and 41.2% of the Beers’ criteria were 
breached, whereas in the NI dataset 46.2% of the STOPP and 38.2% of Beers’ 
criteria were breached (Section 4.11).  A Mann-Whitney U test demonstrated that 
there was no statistically significant difference between the PIP incidence as defined 
by STOPP between the two dataset.  
 
Other recent studies have demonstrated that the STOPP criteria are significantly 
superior in the detection of ADEs causing hospitalisation versus Beers’ criteria 
(Gallagher et al. 2008; Gillespie et al. 2010).  This suggests that STOPP may be a 
more relevant PIP detection tool in secondary care setting than Beers’ criteria.  The 
findings from this study also demonstrate the superiority of STOPP over Beers in the 
identification of potential PIMs in long term care facilities, although the reproducibility 
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of these findings needs to be tested in other long term care facilities, in the RoI, NI 
and internationally. 
 
Comparison of the NIC of PIP between each screening tool 
Inappropriate prescribing, whilst having medical and social consequences, by 
inference, also can contribute to significant economic costs.  The monthly NIC of 
medicines identified as potentially inappropriate in the RoI dataset using the STOPP 
criteria (€9,305.84 (£8,198.97)) was greater than that identified by the Beers’ criteria 
(€2,227.68 (£1,962.71)) (Table 18).  Similarly in the NI dataset the NIC of instances 
of PIP identified by the STOPP criteria (£3,953.28 (€4,486.98) were greater than 
those identified by the Beers’ criteria (£1,380.23 (€1,566.56) (Table 18). These 
differences in price reported for the instances of PIP in the RoI compared to NI could 
be attributed to two reasons; one reason for this variation in price may be because 
nearly half the medications for the residents in NI were prescribed generically 
(48.5%), with less than a third being prescribed generically in the RoI dataset 
(28.4%); the majority were prescribed by brand which are generally more expensive 
than equivalent generics.  Another reason for this significant difference in the price 
could be attributed to the fact that the NIC of the majority of medications in the RoI is 
significantly more expensive than the equivalent drugs NIC in NI.  Some examples of 
the NIC differences between the two datasets were as follows: 
 
• In NI the NIC of a 28 day supply of lanzoprazole 30mg once daily was £2.79 
(€3.17), whereas in the RoI an equivalent supply of the cheapest available 
generic of lansoprazole “Zomel®” the NIC was €22.05 (£25.03), but for the 
majority of the patients in the RoI prescribed the proprietary brand “Zoton®” the 
NIC for a 28 day supply was €38.70 (£34.10).   
• In NI the NIC of a 28 day supply of Risperidone 0.5mg was £1.89 (€2.15), 
whereas in the Republic of Ireland the NIC of an equivalent supply was €8.77 
(£7.73). 
• In NI the NIC for a 28 day supply of olanzapine “Zyprexa® 2.5mg once daily” 
was £21.85 (€24.80), but the equivalent NIC of the same medication in the RoI 
was €47.16 (£41.55). 
• In NI the NIC for a 28 day supply of the opioid patch; “Durogesic® 50mcg/hr one 
every three days” was £96.72 (£109.78), but the equivalent NIC to supply this 
medicine in the RoI was €156.90 (€138.24). 
 
Using the NIC to define cost means that other variables such as VAT and dispensing 
fees which can distort the overall price are ignored.  Although this NIC itself may vary 
from country to country, using just one cost, the NIC, allows direct comparison 
regarding the magnitude of the differences in costs calculated for each screening 
tool.  From an economic perspective, STOPP identified more costly medicines as 
potentially inappropriate than Beers’ criteria.  
 
As STOPP is physiological system based, it is much easier to use than the Beers’ 
criteria. All medicines listed on the STOPP are available in the Republic of Ireland 
and the UK and all explicit rules of avoidance are supported by peer reviewed 
evidence and are difficult to dispute.  STOPP was easy to use and was time efficient. 
On average, STOPP criteria were fully deployed within approximately 3 minutes, 
although there was a short but significant learning curve with STOPP until one was 
fully familiar with the criteria. 
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Long term care facilities 
The potential for the development of a pharmacist-led medication usage review 
(MUR) service for patients residing permanently in long term care facilities has not 
yet been explored in RoI.  This study intended to estimate the scale of the overall 
incidence of PIPs and from this future work could focus on the development of such 
a MUR service.  This study investigated the rate of PIP in residents from nursing 
homes / long term care facilities in the greater Cork region and Northern Ireland and 
found that a significant proportion of older residents in both datasets were prescribed 
at least one instance of PIP (RoI: 54.3% and NI: 56.8% using Beers’ criteria (Table 
8) and RoI: 73.0% and NI: 67.0% using the STOPP criteria (Table 8)).  The rate of 
PIP reported for patients residing in long term care facilities was considerably high, 
but is consistent with another study carried out by Ryan et al. in 2009 which reported 
a STOPP PIP prevalence of 57%, when the “prn” medicines were excluded, of 
residents in three long term care facilities in the greater Cork Region  
 
In terms of the medication usage of residents in long term care facilities, this study 
showed that residents in these facilities in both the RoI and NI were commonly 
prescribed medications for disorders of the CNS, which were prescribed more 
frequently than medicines for the CVS (Figure 4 and 6).  Almost a third of the PIP 
identified by the STOPP tool in the RoI was due to medicines prescribed for the CNS 
(32.2%) and over a third of PIP identified by the STOPP tool in the NI dataset were 
attributable to medications from this class, not counting the CNS medicines involved 
in the PIP identified for “duplication of therapy” class (Table 8).  Several studies have 
shown that the prescribing of medicines for the CNS in these patients contributes 
significantly to the medication problems identified for these patients (Alexopoulos et 
al. 2004; Maixner et al. 1999; Ruths et al. 2003; Stevenson et al. 2010).  
 
With respect to the applicability of criteria to these datasets of residents, the STOPP 
criteria performed favourably over the Beers’ criteria in terms of the identification rate 
of PIMs. In the NI dataset a Wilcoxon signed ranks test demonstrated a significant 
difference in the number of instances of PIP identified by each tool (z= -4.135; 
p<0.01; Section 4.11.2).  Similarly, a Wilcoxon signed rank test demonstrated a 
significant difference in the instances of PIP identified by each tool in the RoI dataset 
(z=-6.075; p<0.01; Section 4.11.2).  More of the STOPP criteria were utilised to 
identify PIMs than the Beers’ criteria, reiterating points made previously that many of 
the Beers’ criteria are redundant in the Irish and European setting.  While this current 
study did not investigate the association between the occurrence of PIP and 
hospitalisation, studies using Beers’ criteria in older patients residing in long-term 
care facilities have previously found significant correlations between PIP and 
hospitalisation (OR=1.69; p-value<0.01) and death  (OR=1.78; p-value<0.01) (Lau et 
al. 2005).  Thus, the need to improve prescribing quality in these patients is 
imperative.  
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6.0 Conclusion / Summary 
In this study, patients from NI and RoI datasets of older residents in long term care 
facilities were studied.  Overall the rates of PIP were found to be similar.  Due to the 
small sample size used in this study it is not possible to generalise these findings to 
long term care facilities across the entire island of Ireland.  A much larger, 
randomised controlled trial would be required in order to fully quantify the prevalence 
of PIP.  Although residents in each dataset were prescribed similar classes of 
medicines, variation in the choice of medicines within particular classes existed 
between datasets.  The overall PIP rate identified for the RoI dataset was 54.3% 
using the Beers’ criteria (41.6% excluding “prn” medicines) and 73.0% (66.0% 
excluding “prn” medicines) using the STOPP criteria, compared to that of an overall 
PIP rate identified in the NI dataset of 56.8% (48.6% excluding “prn” medicines) 
using the Beers’ criteria and PIP rate of 67.0% (60.0% excluding “prn” medicine) 
using the STOPP criteria. The total number of medicines prescribed was positively 
associated with the identification of PIP as defined by both sets of criteria. 
Prevention of IP in late life is crucial for avoidance of potential ADEs, as well as 
limiting costs of medication.  The routine application of a screening tool like STOPP 
could offer a reasonably inexpensive and time efficient method of pharmacotherapy 
optimisation.  One interesting finding in both datasets was that advancing age was 
actually significantly associated with a reduction in the number of medicines 
prescribed, which contradicts most of the evidence in the published literature. 
Whether this association would still exist if residents were under 65 or if community 
dwelling elders had been included in the study is questionable.  
 
Prescribing is both an art and a science, and prescribing in older patients can often 
prove especially complicated and daunting.  Although care plans, guidelines and 
algorithms exist to somewhat standardise prescribing patterns and practices, these 
are only intended to complement a physician’s clinical knowledge and it is crucial 
that they are balanced against the expertise and experience of each individual doctor 
so that the needs and circumstances of each individual resident can always be taken 
into consideration.  
 
Further research in terms of a randomised controlled trial to measure the impact of 
these screening tools on patient-specific outcomes is also under investigation. 
6.1 Limitations  
A major drawback of this study was that the medicines identified as inappropriate 
according to set criteria were potentially inappropriate and the residents were not 
actually examined to determine if there was any level of harm evident from the PIM 
identified.  
 
The PIP rates identified by the criteria may be a conservative estimate, since over 
the counter (OTC) medicines were not included in the analysis. OTC medicines were 
excluded because the relevant information was not collected in the Northern Ireland 
arm of the study; also residents in the nursing home setting receive continual care 
and very rarely have access to OTC medications.  Also a number of issues were 
raised relating to the interpretation of different diagnosis/conditions between the two 
datasets.  As the two datasets were recorded by a number of different researchers, 
the detail of information recorded (medical diagnosis, biochemical data) may have 
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varied between both datasets e.g. a resident has a history of constipation but 
requires long term laxative therapy, one person could report that this resident suffers 
from long term constipation, while another may not have recorded this as an ongoing 
problem because a physician has not diagnosed the resident with chronic 
constipation.  This is also the case for individuals who consistently exhibit a low 
cognitive function e.g. one person may classify a resident as having dementia 
whereas another might just say s/he is cognitively impaired. This variation in 
diagnosis could significantly influence the PIP occurrence rate as a number of the 
criteria in the STOPP and Beers’ CD list of criteria take diagnosis into consideration 
and therefore this can result in false positive or conversely false negative results.   
 
Although the NIC gives a clear indication of the cost of medicines prescribed, it is not 
indicative of all costs involved and also it is a conservative estimate as when a 
medication was prescribed generically, the price calculated was for the cheapest 
available generic and so the overall NIC costs in theory could have been significantly 
greater.  On the other hand when a medications was prescribed “prn” the price was 
calculated for a seven day supply and some residents might not have received 
seven days of the medication in any given month or conversely some residents could 
receive more than a seven day supply in the month, although this was somewhat 
counter balanced by the fact that the NIC relating to the PIP was quoted for both the 
total number of instances of PIP including and excluding “prn” medicines. A much 
more robust trial is necessary to determine the economic and tangible clinical 
benefits in terms of reduction of ADEs (e.g. falls), cost, hospitalisation and mortality 
from routine screening of medicines using the STOPP tool.  
Further work 
This work has highlighted a number of areas of prescribing concern, for example, the 
long term use of both benzodiazepines and hypnotics, in older residents residing in 
long term care facilities.  Each of these individual areas should be further 
investigated to determine the underlying reason(s) for the prescribing concerns in 
these areas and strategic methods of addressing and preventing further issues 
should be developed on a national level. 
 
As with other screening tools identified in the literature, STOPP criteria are in need of 
continued updating and revision.  This update of the STOPP criteria is already under 
way and we are looking at the possibility of incorporating a severity level with 
regards to the instance of IP.  In addition, each prescribing indicator should be 
supported by an evidence based recommendation to advise clinicians on appropriate 
alternatives to the identified PIM.  Any alterations made to the current existing 
screening tools should be validated by the Delphi validation method, in accordance 
with the methods used for the initial version.  
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Appendix 3 
 
ATC Codes 
 
A  Alimentary tract and metabolism 
B  Blood and blood forming organs 
C  Cardiovascular System 
D  Dermatologicals 
G  Genito urinary system and sex hormones 
H  Systemic hormonal preparations, excluding sex hormones and insulins 
J  Anti-infectives for systemic use 
L  Anti-neoplastic and immunomudulating agents 
M  Musculo-skeletal system 
N  Nervous System 
P  Anti-parasitic products, insecticides and repellents 
R  Respiratory system 
S  Sensory organs 
V  Various 
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Appendix 4 
 
Charlson’s Comorbidity Index 
 
Assigned Weights for diseases Conditions 
1 Myocardial Infarction 
Congestive Heart Failure 
Peripheral Vascular Disease 
Cerebrovascular Disease 
Dementia 
Chronic Pulmonary Disease 
Connective Tissue Disease 
Ulcer Disease 
Mild Liver Disease 
Diabetes 
2 Hemiplegia 
Moderate to Severe Renal Disease 
Diabetes with End Organ Damage 
Any Tumour 
Leukemia 
Lymphoma 
3 Moderate or Severe Liver Disease 
6 Metastatic Solid Tumour 
AIDS 
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Appendix 5 
Beers’ criteria considering diagnosis 
Considering diagnosis  
Diagnosis Drug 
Heart failure Disopyramide and high sodium content drugs 
Hypertension Phenylpropanolamine hydrochloride, pseudoephedrine, 
diet pills and amphetamines 
Gastric of duodenal 
ulcers 
NSAIDs and aspirin 
Seizures or epilepsy Clozapine, chlorpromazine, thioridazine and thiothixene 
Blood clotting disorders 
or receiving anticoagulant 
therapy 
Aspirin, NSAIDs, dipryidamole, ticlodipine and 
clopidogrel 
Bladder outflow 
obstruction 
Anticholinergics and antihistamines, GI antispasmodic 
drugs, muscle relaxants, oxybutynin, flavoxate, 
anticholinergics, antidepressants, decongestants and 
tolteridine. 
Stress incontinence α-blockers, anticholinergics, tricyclic antidepressants 
(imipramine hydrochloride, doxepin hydrochloride and 
amitriptyline hydrochloride) and long-acting 
benzodiazepines. 
Arrhythmias Tricyclic antidepressants (imipramine hydrochloride, 
doxepin hydrochloride and amitriptyline hydrochloride) 
Insomnia Decongestants, theophylline, methylphenidate, MAOI’s 
and amphetamines 
Parkinson disease Metoclopramide, conventional antipsychotics and tacrine 
Cognitive impairment Barbiturates, anticholinergics, antispasmodics, muscle 
relaxants and CNS stimulants: dextroamphetamine, 
methylphenidate, methamphetamine and pemolin. 
Depression Long-term benzodiazepine use. Sympatholytic agents: 
methyldopa, reserpine and guanethidine. 
Anorexia and malnutrition CNS stimulants: dextroamphetamine, methylphenidate, 
methamphetamine, pemolin and fluoxetine 
Syncope or falls Short to intermediate acting benzodiazepine and tricyclic 
antidepressants (imipramine hydrochloride, doxepin 
hydrochloride and amitriptyline hydrochloride) 
SIADH/hyponatraemia SSRIs: fluoxetine, citalopram, fluvoxamine, paroxetine 
and sertraline 
Seizure disorder Bupropion 
Obesity Olanzapine 
COPD Long-acting benzodiazepines: chlordiazepoxide, 
chlordiazepoxide- amitriptyline, clidinium-
chlordiazepoxide, diazepam, quazepam, halazepam and 
chlorazepate. ß-blockers: propranolol. 
Constipation Calcium channel blockers, anticholinergics, tricyclic 
antidepressants (imipramine hydrochloride, doxepin 
hydrochloride and amitriptyline hydrochloride) 
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Beers' criteria independent of diagnosis 
Drug Drug 
Propoxyphene and combination products Diphenhydramine 
Indomethacin Ergot mesyloids and cyclandelate 
Pentazocine Ferrous sulphate >325mg 
Trimethobenzamide All barbiturates (except Phenobarbital) 
except when used to control seizures 
Muscle relaxants and antispasmodics: 
methocarbamol, carisprodol, oxybutynin, 
chloroxazone, metaxalone and 
cyclobenzaprine (do not consider 
extended release oxybutynin) 
Long-term use of full dosage, longer 
half-life, non-COX-selective NSAIDs: 
naproxen, oxaprozin and piroxicam. 
Flurazepam Ticlopidine 
Amitriptyline, chlordiazepoxide- 
amitriptyline and perphenazine- 
amitriptyline 
Ketorolac 
Doxepin Amphetamines and anorexic agents 
Mepobramate Meperidine 
Doses of short acting benzodiazepines: 
doses greater than lorazepam 3mg; 
oxazepam 60mg; alprazolam 2mg; 
temazepam 15mg; triazolam 0.25mg. 
Daily fluoxetine 
Chlordiazepoxide, chlordiazepoxide- 
amitriptyline, clidinium-chlordiazepoxide, 
diazepam, quazepam, halazepam and 
chlorazepate 
Long-term use of stimulant laxatives: 
bisacodyl, cascara sagrada and neoloid 
except in the presence of opiate 
analgesic use 
Long-acting benzodiazepines Amiodarone 
Disopyramide Orphenadrine 
Digoxin (should not exceed 0.125mg daily, 
except when treating atrial arrhythmias 
Guanethidine 
Short-acting dipyridamole. Do not consider 
the long-acting dipyridamole except in 
patients with artificial heart valves 
Guanadrel 
Methyldopa and methyldopa-
hydrochlorothiazide 
Cyclandelate 
Reserpine at doses >0.25mg Isoxsurpine 
Chlorpropramide Nitrofurantoin 
Gastrointestinal antispasmodic 
drugs:dicyclomide, hyoscyamine, 
propantheline, belladonna alkoloids and 
clinidium-chlordiazepoxide 
Doxazosin 
Anticholinergics and anthistamines: 
Chlorpheniramine, diphenhydramine, 
hydroxyzine, cyproheptadine, 
promethazine, tripelennamine and 
dexchlorpheniramine 
Methyltestosterone 
Thioridazine Mesoridazine 
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Appendix 6 
STOPP: Screening Tool of Older People’s potentially inappropriate 
Prescriptions 
The following drug prescriptions are potentially inappropriate in persons aged ≥ 65 
years of age. 
A. Cardiovascular System 
1. Digoxin at a long-term dose > 125µg/day with impaired renal function∗ (increased 
risk of toxicity). 
2. Loop diuretic for dependent ankle oedema only i.e. no clinical signs of heart failure 
(no evidence of efficacy, compression hosiery usually more appropriate). 
3. Loop diuretic as first-line monotherapy for hypertension (safer, more effective 
alternatives available). 
4. Thiazide diuretic with a history of gout (may exacerbate gout).  
5. Non cardioselective Beta-blocker with Chronic Obstructive Pulmonary Disease 
(COPD) (risk of increased bronchospasm). 
6. Beta-blocker in combination with verapamil (risk of symptomatic heart block). 
7. Use of diltiazem or verapamil with NYHA Class III or IV heart failure (may worsen 
heart failure). 
8. Calcium channel blockers with chronic constipation (may exacerbate 
constipation).  
9. Use of aspirin and warfarin in combination without histamine H2 receptor antagonist 
(except cimetidine because of interaction with warfarin) or proton pump inhibitor (high risk of 
gastrointestinal bleeding).  
10. Dipyridamole as monotherapy for cardiovascular secondary prevention (no 
evidence for efficacy) 
11. Aspirin with a past history of peptic ulcer disease without histamine H2 receptor 
antagonist or Proton Pump Inhibitor (risk of bleeding). 
12.Aspirin at dose > 150mg day (increased bleeding risk, no evidence for increased 
efficacy). 
13. Aspirin with no history of coronary, cerebral or peripheral vascular symptoms or 
occlusive event (not indicated). 
14. Aspirin to treat dizziness not clearly attributable to cerebrovascular disease (not 
indicated). 
15. Warfarin for first, uncomplicated deep venous thrombosis for longer than 6 
months duration (no proven added benefit). 
16. Warfarin for first uncomplicated pulmonary embolus for longer than 12 months 
duration (no proven benefit). 
17. Aspirin, clopidogrel, dipyridamole or warfarin with concurrent bleeding disorder 
(high risk of bleeding). 
∗ Serum Creatinine > 150 µmol/L, or estimated GFR <50ml/min.  
B. Central Nervous System and Psychotropic Drugs. 
1. Tricyclic antidepressants (TCA’s) with dementia (risk of worsening cognitive 
impairment). 
2. TCA’s with glaucoma (likely to exacerbate glaucoma). 
3. TCA’s with cardiac conductive abnormalities (pro-arrhythmic effects). 
4. TCA’s with constipation (likely to worsen constipation). 
5. TCA’s with an opiate or calcium channel blocker (risk of severe constipation). 
6. TCA’s with prostatism or prior history of urinary retention (risk of urinary retention). 
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7. Long-term (i.e. > 1 month), long-acting benzodiazepines e.g. chlordiazepoxide, 
fluazepam, nitrazepam, chlorazepate and benzodiazepines with long-acting 
metabolites e.g. diazepam (risk of prolonged sedation, confusion, impaired balance, 
falls). 
8. Long-term (i.e. > 1 month) neuroleptics as long-term hypnotics (risk of confusion, 
hypotension, extra-pyramidal side effects, falls). 
9. Long-term neuroleptics ( > 1 month) in those with parkinsonism (likely to worsen 
extra-pyramidal symptoms) 
10. Phenothiazines in patients with epilepsy (may lower seizure threshold). 
11. Anticholinergics to treat extra-pyramidal side-effects of neuroleptic medications 
(risk of anticholinergic toxicity). 
12. Selective serotonin re-uptake inhibitors (SSRI’s) with a history of clinically 
significant hyponatraemia (non-iatrogenic hyponatraemia <130mmol/l within the 
previous 2 months). 
13. Prolonged use (> 1 week) of first generation antihistamines i.e. diphenydramine, 
chlorpheniramine, cyclizine, promethazine ( risk of sedation and anti-cholinergic side 
effects).  
C. Gastrointestinal System 
1. Diphenoxylate, loperamide or codeine phosphate for treatment of diarrhoea of unknown 
cause (risk of delayed diagnosis, may exacerbate constipation with overflow diarrhoea, may 
precipitate toxic megacolon in inflammatory bowel disease, may delay recovery in 
unrecognised gastroenteritis). 
2. Diphenoxylate, loperamide or codeine phosphate for treatment of severe infective 
gastroenteritis i.e. bloody diarrhoea, high fever or severe systemic toxicity (risk of 
exacerbation or protraction of infection) 
3. Prochlorperazine (Stemetil) or metoclopramide with Parkinsonism (risk of 
exacerbating Parkinsonism). 
4. PPI for peptic ulcer disease at full therapeutic dosage for > 8 weeks (dose 
reduction or earlier discontinuation indicated). 
5. Anticholinergic antispasmodic drugs with chronic constipation (risk of exacerbation 
of constipation). 
D. Respiratory System. 
1. Theophylline as monotherapy for COPD. (safer, more effective alternative; risk of 
adverse effects due to narrow therapeutic index) 
2. Systemic corticosteroids instead of inhaled corticosteroids for maintenance 
therapy in moderate-severe COPD (unnecessary exposure to long-term side-effects 
of systemic steroids). 
3. Nebulised ipratropium with glaucoma (may exacerbate glaucoma). 
E. Musculoskeletal System1. Non-steroidal anti-inflammatory drug (NSAID) with 
history of peptic ulcer disease or gastrointestinal bleeding, unless with concurrent 
histamine H2 receptor antagonist, PPI or misoprostol (risk of peptic ulcer relapse). 
2. NSAID with moderate-severe hypertension (risk of exacerbation of 
hypertension).3. NSAID with heart failure (risk of exacerbation of heart failure). 
4. Long-term use of NSAID (>3 months) for symptom relief of mild osteoarthtitis 
(simple analgesics preferable and usually as effective for pain relief) 
5. Warfarin and NSAID together (risk of gastrointestinal bleeding). 
6. NSAID with chronic renal failure∗ (risk of deterioration in renal function). 
7. Long-term corticosteroids (>3 months) as monotherapy for rheumatoid arthrtitis or 
osterarthritis (risk of major systemic corticosteroid side-effects). 
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8. Long-term NSAID or colchicine for chronic treatment of gout where there is no 
contraindication to allopurinol (allopurinol first choice prophylactic drug in gout) 
∗ Serum Creatinine > 150 µmol/L, or estimated GFR 20-50ml/min. 
F. Urogenital System 
1. Bladder antimuscarinic drugs with dementia (risk of increased confusion, 
agitation). 
2. Antimuscarinic drugs with chronic glaucoma (risk of acute exacerbation of 
glaucoma). 
3. Antimuscarinic drugs with chronic constipation (risk of exacerbation of 
constipation). 
4. Antimuscarinic drugs with chronic prostatism (risk of urinary retention). 
5. Alpha-blockers in males with frequent incontinence i.e. one or more episodes of 
incontinence daily (risk of urinary frequency and worsening of incontinence). 
6. Alpha-blockers with long-term urinary catheter in situ i.e. more than 2 months 
(drug not indicated). 
G. Endocrine System 
1. Glibenclamide or chlorpropamide with type 2 diabetes mellitus (risk of prolonged 
hypoglycaemia). 
2. Beta-blockers in those with diabetes mellitus and frequent hypoglycaemic 
episodes i.e. ≥ 1 episode per month (risk of masking hypoglycaemic symptoms). 
3. Oestrogens with a history of breast cancer or venous thromboembolism 
(increased risk of recurrence) 
4. Oestrogens without progestogen in patients with intact uterus (risk of endometrial 
cancer). 
H. Drugs that adversely affect fallers. 
1. Benzodiazepines (sedative, may cause reduced sensorium, impair balance). 
2. Neuroleptic drugs (may cause gait dyspraxia, Parkinsonism). 
3. First generation antihistamines (sedative, may impair sensorium). 
4. Vasodilator drugs with persistent postural hypotension i.e. recurrent > 20mmHg 
drop in systolic blood pressure (risk of syncope, falls).5. Long-term opiates in those 
with recurrent falls (risk of drowsiness, postural hypotension, vertigo). 
I. Analgesic Drugs 
1. Use of long-term powerful opiates e.g. morphine or fentanyl as first line therapy for 
mild-moderate pain (WHO analgesic ladder not observed). 
2. Regular opiates for more than 2 weeks in those with chronic constipation without 
concurrent use of laxatives (risk of severe constipation). 
3. Long-term opiates in those with dementia unless indicted for palliative care or 
management of moderate/severe chronic pain syndrome (risk of exacerbation of 
cognitive impairment). 
J. Duplicate Drug Classes 
Any duplicate drug class prescription e.g. two concurrent opiates, NSAID’s, SSRI’s, 
loop diuretics, ACE inhibitors (optimisation of monotherapy within a single drug class 
should be observed prior to considering a new class of drug). 
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